document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registranttable content gilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item submission matter vote security holder ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead sciences truvada viread emtriva hepsera ambisome vistide letairis atripla register trademark belong bristolmyer squibb gilead sciences llc macugen register trademark belong osi pharmaceuticals inc sustiva register trademark bristolmyer squibb company tamiflu register trademark belong f hoffmannla roche ltd flolan volibris register trademarks glaxosmithkline inc report include trademark service mark trade name companiestable content annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forwardlooke statement include statement overall trend operate cost trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify risk factor begin risk uncertainty assumption refer include limited follow ability maintain continue increase sale hiv product ability commercialize new product expand indication exist product significant competition face significant safety issue arise market product product candidate ability comply complex food drug administration fda comparable international regulation result anticipate timeline clinical trial uncertain support continue development product pipeline reliance thirdparty contract research organization conduct clinical trial inability directly control timing conduct expense quality clinical trial ability obtain material supply necessary conduct clinical trial manufacture sell product dependence relationship company sale marketing performance revenue ability protect patent intellectual property right domestically internationally ability operate infringe patent proprietary right party risk factor list time time filing securities exchange commission sec give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof require federal security law rule regulation sec undertake specifically decline obligation update statement publicly announce result revision forward look statement distribution report result new information future event change assumption table content item business overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california operations north america europe australia date focus effort bring novel therapeutic treatment lifethreatening disease market continue seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy product truvada emtricitabine tenofovir disoproxil fumarate oral formulation dose day combination therapy treat human immunodeficiency virus hiv infection adult fixeddose combination antihiv medication viread tenofovir disoproxil fumarate emtriva emtricitabine promote truvada united states commercial team sell united states exclusively wholesale channel promote sell truvada europe commercial team distributor australia new zealand commercial team certain latin american middle eastern asian country distributor promote sell truvada japan corporate partner japan tobacco inc japan tobacco addition truvada available substantially reduce price certain develop world country include gilead access program atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dose day treatment hiv infection adult atripla oncedaily single tablet regimen hiv intend standalone therapy combination antiretroviral fixeddose combination antihiv medication viread emtriva bristol myerssquibb company sustiva efavirenz promote atripla joint venture partner bristol myerssquibb company bms united states companys commercial team sell joint venture bristol myerssquibb gilead sciences llc united states exclusively wholesale channel atripla approve sale european union december currently sell united kingdom germany austria plan promote atripla jointly bms majority country europe responsible selling distribute product country limited number central eastern european country bms thirdparty distributor sole promote sell distribute company addition atripla available substantially reduce price certain develop world country collaboration merck co inc merck viread oral formulation nucleotide analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult promote viread united states commercial team sell united states exclusively wholesale channel promote sell viread europe commercial team distributor australia new zealand commercial team certain latin american middle eastern asian country distributor promote sell viread japan corporate partner japan tobacco addition viread available substantially reduce price certain develop world country include gilead access program emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva approve combination therapy treat hiv infection child promote table content emtriva united states commercial team sell united states exclusively wholesale channel promote sell emtriva europe commercial team distributor australia new zealand commercial team certain latin american middle eastern country distributor promote sell emtriva japan corporate partner japan tobacco hepsera adefovir dipivoxil oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dose day treat chronic hepatitis b hepsera approve sale united states treatment chronic hepatitis b adult evidence active viral replication evidence persistent elevation serum aminotransferase alt ast histologically active liver disease commercial team promote hepsera united states sell united states exclusively wholesale channel promote sell hepsera europe commercial team distributor australia new zealand commercial team license right commercialize hepsera solely treatment hepatitis b asia latin america certain territories glaxosmithkline inc gsk ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat invasive fungal infection cause fungal specie corporate partner astellas pharma inc astellas promote sell ambisome united states canada promote sell ambisome europe australia new zealand commercial team distributor use distributor promote sell ambisome certain latin american middle eastern asian country include india exclude japan dainippon sumitomo pharma co ltd responsible promotion distribution letairis ambrisentan endothelin receptor antagonist era indicate treatment pulmonary arterial hypertension pah group patients class ii iii symptom improve exercise capacity delay clinical worsen letairis approve united states june available special restrict distribution program call letairis education access program leap prescriber pharmacy register leap prescribe sell distribute letairis letairis grant orphan drug status treatment pah united states european union recently receive positive opinion european committee human medicinal product treatment pah market volibris gsk approval exclusive license patent right relate technology letairis united states abbott laboratories inc abbott sublicensed gsk right letairis certain hypertensive condition territory outside united states vistide cidofovir injection antiviral medication treatment cytomegalovirus retinitis patient aid vistide approve sale united states sell product exclusively wholesale channel country outside united states vistide sell pfizer inc pfizer flolan epoprostenol sodium inject medication longterm intravenous treatment primary pulmonary hypertension pulmonary hypertension associated scleroderma spectrum disease new york heart association class iii class iv patient respond adequately conventional therapy license agreement distribution supply agreement gsk exclusive right market promote distribute flolan sterile diluent flolan united states april flolan distribute united states specialty pharmacy table content follow table list aggregate product sale major product thousand total total total product product product sale sale sale hiv product truvada atripla viread emtriva total hiv product hepsera ambisome total product sale item note consolidated financial statement page include annual report total revenue geographic area royalty product tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu class prescription drug call neuraminidase inhibitor tamiflu approve treatment influenza child adult country include united states japan european union approve prevention influenza child adults united states japan european union develop tamiflu f hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture party sell tamiflu worldwide subject obligation pay royalty base percentage net sale roche generate sale tamiflu worldwide macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen approve fda united states december sale commence january february product receive marketing approval sale european union macugen develop osi pharmaceuticals inc osi technology license promote united states osi osi hold exclusive right manufacture sell macugen united states pfizer hold exclusive right manufacture sell macugen rest world receive royalty osi base sale macugen worldwide commercialization distribution international commercial sale operation marketing subsidiary australia austria canada france germany greece ireland italy new zealand portugal spain switzerland turkey united kingdom united states process establish marketing subsidiary belgium denmark finland netherlands norway sweden intend terminate distributor agreement cover territory commercial team promote truvada viread emtriva hepsera ambisome letairis flolan direct field contact physician hospital clinic healthcare provider table content sell distribute truvada viread emtriva hepsera vistide united states exclusively wholesale channel corporate partner astella promote sell distribute ambisome united states letairis flolan sell distribute exclusively specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling letairis available leap special restrict distribution program sell distribute truvada viread emtriva hepsera ambisome europe commercial team thirdparty distributor australia new zealand commercial team sell distribute truvada viread emtriva hepsera ambisome country outside united states europe include country asia latin america middle east australia new zealand africa territory exception australia new zealand enter agreement thirdparty distributor grant exclusive right sell product particular territory specify period time agreement provide collaborative effort distributor obtain regulatory approval product specify territory agreement generally grant distributor right promote product territory promote atripla united states joint venture partner bms respective commercial team direct field contact physician hospital clinic healthcare provider involve treatment patient hiv atripla approve sale european union december currently sell united kingdom germany austria plan promote atripla jointly bms majority country europe responsible selling distribute product country limited number central eastern european country bms thirdparty distributor sole promote sell distribute company small group noneuropean union eastern central european country atripla promote bms directly thirdparty distributor product sale large wholesaler account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total revenue follow table summarize percent total revenue attribute product sale wholesaler year end december cardinal health inc mckesson corp amerisourcebergen corp competition product development program target number area include viral fungal respiratory cardiovascular disease commercially available product treatment disease large number company institution spend considerable amount money resource develop additional product treat disease product compete available product base primarily efficacy safety tolerability table content acceptance doctor ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv product hiv landscape competitive complex treatment trend continue evolve grow number antihiv drug currently sell advanced stage clinical development approximately brand hiv drug available united states product primarily compete fixeddose combination product nucleotidenucleoside reverse transcriptase inhibitor nrti class include combivir lamivudine zidovudine epzicomkivexa abacavir lamivudine trizivir abacavirlamivudinezidovudine sell gsk company hiv product compete nrti class include bms roche hiv product compete broadly hiv product boehringer ingelheim gmbh merck abbott tibotec therapeutic division ortho biotech products lp bmss videx ec didanosine ddi generic hiv product united states gsk retrovir zidovudine face generic competition united states result launch generic zidovudine date little impact generic didanosine generic zidovudine price hiv product price decrease hiv product result long term ambisome ambisome face strong competition current expect competitor competition current expect competitor erode revenue receive sale ambisome ambisome face competition vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin b product include abelcet amphotericin b lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin b liposomal sell genpharma sa argentina bms numerous generic manufacturer sell conventional amphotericin b compete ambisome aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association hepsera hepsera face significant competition exist expect therapy treat patient chronic hepatitis b hepsera face increase competition baraclude entecavir oral nucleoside analogue develop bms launch united states tyzekasebivo telbivudine oral nucleoside analogue develop novartis pharmaceutical corporation novartis sale united states european union china compete epivirhbvzeffix lamivudine develop gsk collaboration shire pharmaceuticals group plc sell major country north south america europe asia table content hepsera competes establish immunomodulatory therapy include introna interferon alfab sell schere plough corporation major country north south america europe asia pegasys pegylate interferon alfaa injectable drug similar introna sell roche treatment chronic hepatitis b letairis letairis compete directly tracleer bosentan sell actelion ltd indirectly pah product united therapeutics corporation pfizer vistide vistide compete number drug treat cytomegalovirus retinitis include cytovene iv cytovene ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valcyte valganciclovir market roche foscavir foscarnet intravenous drug sell astrazeneca plc vitravene fomivirsen drug inject directly eye sell cibavision flolan flolan compete primarily remodulin treprostinil form prostacyclin administer continuous subcutaneous infusion continuous intravenous infusion sell united therapeutics corporation united states flolan compete ventavis iloprost inhale form prostacyclin sell affiliate actelion ltd united states addition patent covering flolan expire generic pharmaceutical company launch generic version flolan united states tamiflu tamiflu compete relenza zanamivir antiinfluenza drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine rimantadine oral tablet inhibit replication influenza virus biocryst pharmaceuticals inc develop injectable formulation peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trial macugen macugen compete primarily visudyne verteporfin injection sell novartis connection photodynamic therapy lucentis ranibizumab sell genentech inc number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program anticipate face increase competition future exist future competitor introduce new product market new technology available determine exist product new product competitor develop effective effectively market sell develop competitive product render technology product obsolete noncompetitive recover investment resource develop product collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include financial accounting impact business find item note consolidated financial statement page include annual report table content commercial collaboration follow list representative commercial collaboration year commercial collaboration partner product sign astella ambisome iocbrega truvada atripla viread hepsera vistide emory truvada atripla emtriva roche tamiflu pfizer vistide macugen sumitomo ambisome osi macugen abbott letairis gsk hepsera letairis flolan japan tobacco truvada viread emtriva bms atripla astellas pharma inc astellas enter agreement astella successor fujisawa usa inc relate right market ambisome agreement astella responsible promote ambisome united states canada exclusive marketing right ambisome rest world subject obligation pay royalty astellas connection sale significant market asia include china india japan south korea taiwan astellas collect payment sale ambisome united states canada subject obligation pay royalty astellass gross profit sale ambisome united states canada institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega enter agreement iocbrega relate certain nucleotide compound discover institution agreement receive exclusive right manufacture use sell nucleotide compound obligate pay iocbrega percentage net sale receive sale product contain patented compound subject minimum royalty payment compound cover original agreement include cidofovir active pharmaceutical ingredient vistide adefovir active pharmaceutical ingredient hepsera tenofovir active pharmaceutical ingredient viread active pharmaceutical ingredient truvada atripla december agreement iocbrega amend provide reduce royalty rate future sale product incorporate adefovir tenofovir return upfront payment sign amendment august iocbrega agree waive right royalty sale truvada viread develop country sell product substantially reduce price gilead access program sale atripla distribute merck develop country august execute amendment agreement iocbrega set forth royalty obligation sale product contain tenofovir certain upper low middleincome country sale product contain tenofovir manufacture indian generic company certain specify develop country include india emory university emory april obtain exclusive worldwide license emorys right purify form emtricitabine active pharmaceutical ingredient emtriva table content component truvada atripla use treatment hiv hbv prior july pay royalty emory worldwide net sale product contain emtricitabine july royalty pharma purchase respectively royalty interest own emory exchange elimination emtricitabine royalty payable emory july pay royalty worldwide net sale product contain emtricitabine directly royalty pharma rate proportional share purchase price july payment emory connection amendment restatement exist license agreement emory pertain obligation develop emtricitabine hepatitis b indication f hoffmannla roche ltd hoffmannla roche inc roche september enter development license agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche original agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net sale roche generate tamiflu sale november enter amendment supplement original agreement roche amendment eliminate cost good adjustment royalty calculation retroactive calendar year future calculation amendment provide formation joint manufacturing committee review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis committee consist representative roche amendment option provide specialized sale force supplement roche marketing effort tamiflu exercise date pfizer inc pfizer august grant pfizer exclusive right market sell vistide country outside united states subject payment percentage net product sale vistide pfizer agreement require sell pfizer bulk cidofovir maintain vistide patent connection agreement receive upfront license fee milestone payment obtain marketing approval europe entitle receive certain royalty net sale vistide december osi grant pfizer sublicense relate macugen connection sublicense enter license pfizer term contain agreement osi dainippon sumitomo pharma co ltd sumitomo september enter agreement sumitomo successor sumitomo pharmaceutical co ltd pursuant sumitomo agree develop market ambisome japan agreement amend restate august term restate agreement receive upfront license fee certain milestone payment entitle receive royalty ambisome sale japan agreement require supply sumitomo unlabeled vial ambisome sumitomo package label market distribute japan osi pharmaceuticals inc osi march grant osi worldwide right therapeutic use macugen osi sublicense right macugen territory outside united states pfizer enter license agreement pfizer term contain agreement osi entitle receive payment osi osi reach certain milestone royaltie worldwide net sale macugen subject obligation payment party relate royalty december enter agreement osi fill finish macugen osi abbott laboratories inc abbott october abbott grant exclusive worldwide license develop commercialize ambrisentan active pharmaceutical ingredient letairis therapeutic use agreement require certain milestone payment pay royalty base net sale letairis june fda approve letairis table content treatment pah united states march discuss sublicensed glaxosmithkline inc rights ambrisentan certain hypertensive condition territory outside united states glaxosmithkline inc gsk april grant gsk right commercialize hepsera solely treatment chronic hepatitis b asia latin america certain territory significant include china japan south korea taiwan agreement retain right hepsera united states canada europe australia new zealand turkey receive upfront license fee milestone payment payable licensing agreement gsk responsibility development commercialization hepsera treatment hepatitis b territory addition gsk require pay royalty net sale hepsera gsk hepatitis product epivirhbvzeffix gsk territory hepsera launch japan south korea taiwan china march exclusively sublicense gsk right ambrisentan active pharmaceutical ingredient letairis certain hypertensive condition territory outside united states license agreement receive upfront payment subject achievement specific milestone eligible receive additional milestone payment addition receive royalty base net sale letairis gsk territory gsk option negotiate exclusive sublicense additional therapeutic use letairis gsk territory term license agreement agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval letairis united states canada european economic area party conduct additional development activity territory expense party agree jointly develop letairis new indication license field party pay share external cost associate joint development march receive milestone payment gsk validation european medicine agency marketing authorization application letairis treatment pah march enter license agreement distribution supply agreement gsk exclusive right promote sell distribute flolan sterile diluent flolan united states april addition gsk assign right responsibility respect flolan certain agreement specialty pharmacy distributor extent gross sale flolan united state exceed certain predefine target supply price pay gsk flolan decrease slide scale commence distribution activity flolan united states distribution supply agreement april japan tobacco inc japan tobacco july enter licensing agreement japan tobacco japan tobacco commercialize certain hiv product specifically viread truvada emtriva japan term agreement receive upfront license fee additional cash payment achievement certain milestone japan tobacco require pay royalty net sale product japan march viread approve sale japan march emtriva truvada approved sale japan bristolmyers squibb company bms december enter collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states combination approve use united states july sell atripla bms structure collaboration joint venture form limited liability company call bristolmyers squibb gilead sciences llc term collaboration bms grant royaltyfree sublicense joint venture use respective companyowne technology return grant license joint venture use intellectual property result collaboration economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable truvada emtricitabine tenofovir disoproxil table content fumarate sustiva efavirenz respectively net selling price truvada change time relative net selling price sustiva bmss respective economic interest joint venture vary annually bms share marketing sale effort party provide equivalent sale force effort minimum number year daily operation joint venture govern primary joint committee form bms responsible accounting financial reporting tax reporting product distribution joint venture september bms amend joint venture collaboration agreement allow joint venture sell atripla canada december enter collaboration bms set forth term condition bms commercialize atripla european union norway iceland switzerland liechtenstein bms thirdparty distributor act sell party country responsible thing receive process customer order warehouse product collect sale handle return manufacture atripla coordinate primarily responsible distribution logistic general party share revenue outofpocket expense proportion net selling price truvada emtricitabine tenofovir disoproxil fumarate respect efavirenz respect bms access develop world gilead access program establish truvada viread available substantially reduce price country develop world develop system tiere pricing reflect economic status gross national incomegniper capita disease prevalence low low middleincome country approach allow price therapy base country ability pay example high prevalence exist certain country country relatively high gni country move low price tier accommodate high burden disease support clinical study donation product help define good treatment strategy develop world study support include dart study november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conduct mrc antiretroviral hiv therapy africa trial call dart development antiretroviral therapy study aim study clinical versus laboratory monitoring practice structure treatment interruption continuous antiretroviral therapy adult hiv infection subsaharan africa provide viread cost dart study institute world health january enter agreement institute world health pursuant provide ambisome cost phase clinical trial evaluate ambisome treatment visceral leishmaniasis paromomycin india great global burden visceral leishmaniasis exist clinical trial conduct institute world health partnership world health organization enter number collaboration develop world include aspen pharmacare holdings ltd aspen october enter nonexclusive manufacturing distribution agreement aspen provide manufacture distribution viread truvada certain develop world country include gilead access program november amend agreement aspen amend agreement aspen retain right manufacture distribute viread truvada certain develop world country gilead access program aspen right purchase viread truvada britestock form distribution country right manufacture viread truvada active pharmaceutical ingredient purchase aspen supplier table content approve aspen grant option manufacture distribute generic version emtricitabine tenofovir disoproxil fumarate meet certain regulatory standard execute amend agreement aspen notify intend exercise option manufacture distribute generic product certain develop world country aspen require pay royalty net sale viread truvada generic version emtricitabine tenofovir disoproxil fumarate manufacture distribute aspen generic license enter nonexclusive license agreement indian generic manufacturer grant right produce distribute generic version tenofovir disoproxil fumarate lowincome country world include india lowincome country gilead access program agreement require generic manufacturer meet certain national international regulatory standard include technology transfer enable expeditious production large volume highquality generic version tenofovir disoproxil fumarate addition agreement allow manufacture commercial quantity active pharmaceutical ingredient finish product merck august enter agreement affiliate merck pursuant provide atripla substantially reduce price hivinfecte patient develop country africa caribbean latin america southeast asia utilize different trade dress european tablet agreement manufacture atripla efavirenz supply merck merck handle distribution product country cover agreement international partnership microbicide ipm conrad december enter agreement grant right ipm conrad cooperate agency agency international development usaid committed improve reproductive health expand contraceptive choice woman man develop manufacture prove efficacious arrange distribution resourcelimite country tenofovir microbicide prevent hiv infection research collaboration follow list representative research collaboration research collaboration partner program area year signing university texas system novel compound treatment cardiac hypertrophy heart disease heart failure fibrosis respiratory pulmonary disease abbott laboratories darusentan treatment certain hypertensive condition novartis institute novel compound treatment cardiovascular disease novartis vaccine small molecule therapeutic certain hepatitis c virus hcv drug target genelabs nucleoside rna polymerase inhibitor treatment hcv achillion compound treatment hcv japan tobacco elvitegravir know gs treatment hiv parion p gs epithelial sodium channel enac inhibitor treatment pulmonary disease lgl caspase inhibitor treatment fibrotic disease university texas system december enter license agreement university texas system grant exclusive right certain patent technology relate cardiac hypertrophy heart disease heart failure concurrently enter sponsor research table content agreement university fund research cardiac hypertrophy heart failure university texas southwestern medical center november amend restate sponsor research agreement extend term research collaboration march expand scope research collaboration include research relate fibrosis respiratory pulmonary disease increase funding provide sponsor research concurrently amend restate license agreement provide right license invention arise sponsor research conduct amend restate sponsor research agreement obligate pay certain annual fee percentage sublicense revenue royalty base net sale additionally obligate milestone payment product develop license technology january enter second license agreement amend february november relate sponsor research agreement university texas system amend november amend agreement receive exclusive right certain patent technology relate cardiac hypertrophy heart disease heart failure include invention arise conduct sponsor research research conduct sponsor research agreement complete obligation pay milestone payment plus percentage sublicense revenue royalty base percentage net sale product cover license agreement abbott june enter exclusive worldwide license agreement abbott develop commercialize darusentan condition oncology obligate future milestone payment pay royalty base net sale successfully commercialize drug indication commercialize darusentan certain market abbott market product affect market pay royalty sale darusentan currently study phase clinical trial treatment patient resistant hypertension novartis institutes biomedical research inc novartis institutes october enter research collaboration novartis institute discovery development novel drug treatment cardiovascular disease novartis institute provide research fund exchange right license compound develop collaboration collaboration expand include histone deacetylase inhibitor hdaci program acquire myogen inc myogen novartis institute exclusive option license discovery relevant field limited exception relate hdaci product candidate october relate product candidate hdaci product candidate execution license product candidate novartis institute obligate fund development product candidate payment achievement certain milestone pay royalty sale product successfully commercialize date novartis institutes license drug target compound term collaboration novartis vaccine diagnostic inc novartis vaccine august enter nonexclusive licensing agreement novartis vaccine successor chiron corporation research development commercialization small molecule therapeutic select hcv drug target agreement receive nonexclusive right use novartis vacciness hcv technology develop commercialize product treatment hcv term agreement pay novartis vaccine upfront license fee agree additional payment certain clinical regulatory contractually determined milestone meet additionally obligate royalty payment event product develop licensed technology genelabs technologies inc genelabs september enter license research collaboration agreement genelab research develop commercialize certain genelabss novel nucleoside inhibitor hcv polymerase treatment chronic infection cause hcv conjunction signing agreement pay upfront license fee agreement table content provide support ongoing research nucleoside hcv inhibitor genelabs fund fulltime equivalent year term expire september currently select certain inhibitor development obligate additional payment achievement certain milestone pay royalty future net sale select compound develop approve relation collaboration achillion pharmaceuticals inc achillion november enter exclusive license collaboration agreement achillion pursuant agreement grant worldwide right research development commercialization certain small molecule hcv replication inhibitor involve hcv protease treatment hepatitis c infection collaboration achillion obligate continue development inhibitor compound accord mutually agree development plan completion proofofconcept clinical study hcvinfecte patient cost incur achieve proofof concept share equally achillion contractually agree budget follow proofofconcept study obligate assume responsibility incur cost associate development commercialization compound warrant development achillion option participate commercialization effort future product arise collaboration conjunction signing collaboration pay upfront license fee certain investment achillion equity agree payment achillion achievement certain milestone outline agreement pay royalty future net sale product arise collaboration december achillion begin dose hcvinfecte patient phase clinical study gs know ach treatment hepatitis c infection february base preliminary datum phase b study company decide discontinue development gs company continue explore nsa antagonist discover achillion gilead take lead future preclinical clinical development work appropriate candidate identify japan tobacco march enter licensing agreement japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor know gs country world exclude japan japan tobacco retain right term agreement pay upfront license fee milestone payment additionally obligate additional cash payment achievement certain milestone pay royalty base net sale territory market product parion sciences inc parion august enter exclusive licensing codevelopment agreement parion focus p gs epithelial sodium channel enac inhibitor discover parion agreement grant worldwide commercialization right gs treatment pulmonary disease include cystic fibrosis cf chronic obstructive pulmonary disease noncf bronchiectasis addition parion collaborate research program identify promise enac blockerbase drug candidate utilize parion proprietary enacbased chemistry platform term agreement pay parion upfront payment addition obligate provide research funding pay parion royalty base potential future product sale cash payment achievement certain milestone lg life sciences ltd lgls november enter exclusive license agreement lgl focus development caspase inhibitor treatment fibrotic disease agreement grant commercialization right lglss caspase inhibitor include lb know gs gs investigational caspase inhibitor currently evaluate phase clinical trial patient chronically infect hcv agreement obligate fund collaborative research program year identify potential caspase inhibitor drug candidate term agreement pay lgls license payment obligate fund additional research pay lgls royalty base net product sale obligate milestone payment achievement certain development regulatory table content commercial objective license worldwide exception korea china india lgls retain right lgls retain right develop commercialize caspase inhibitor ophthalmic topical use worldwide research development addition enter collaboration company university medical research institution seek add exist portfolio product internal discovery clinical development program active inlicense product acquisition strategy acquisition myogen corus pharma inc research scientist foster city san dimas california durham north carolina seattle washington westminster colorado engage discovery development new molecule technology hope lead new medicine novel formulation exist drug internal research focus discovery development treatment disease follow area hiv february complete phase study elvitegravir know gs novel integrase inhibitor hiv license japan tobacco discussion fda european medicine evaluation agency emea concern design phase program pende positive outcome discussion hope dose patient phase clinical study elvitegravir quarter complete phase single dose pharmacokinetic study gs healthy volunteer gs novel nucleotide analog design deliver high intracellular concentration active molecule allow low dose high potency result phase study confirm preclinical result delivery high intracellular concentration compound low dose gs result pende discussion fda design phase protocol anticipate dose patient phase study evaluate gs treatmentexperience hiv infect patient confirm nrti resistance half hepatitis hbv november present positive result phase pivotal study compare efficacy safety tenofovir disoproxil fumarate active pharmaceutical ingredient viread versus hepsera patient chronic hepatitis b base datum october file supplemental new drug application nda fda type ii variation emea marketing approval viread treatment chronic hepatitis b adult hcv november release preliminary phase ab data single dose dose sevenday treatment course gs novel nonnucleoside polymerase inhibitor datum demonstrate favorable antiviral activity pharmacokinetic exposure dose evaluate study observe possible qt prolongation mg dose measure cardiovascular safety conduct complete pilot qt study healthy volunteer mg mg doses confirm qt prolongation mg dose prolongation mg dose small believe clinically manageable seek fdas consent reinitiate dose hcvinfecte individual define efficacy safety compound hcv november enter exclusive license agreement lgl focus development caspase inhibitor treatment fibrotic disease agreement grant commercialization right lglss caspase inhibitor include gs lglss lead compound call lb gs investigational table content caspase inhibitor currently evaluate phase clinical trial patient chronic hepatitis c anticipate datum trial end addition research collaboration achillion genelab continue hope development candidate emerge effort respiratory cardiovascular disease respiratory area october present datum second pivotal phase study aztreonam lysine inhalation inhale antibiotic treatment patient cf pulmonary infection pseudomona aeruginosa p aeruginosa november submit nda fda marketing approval aztreonam lysine inhalation mg time daily treatment pulmonary p aeruginosa infection people cf base discussion emea plan submit marketing authorization application second quarter october present datum gs proprietary inhale formulation tobramycin fosfomycin demonstrate compound activity pathogen commonly find patient cf bronchiectasis base preclinical study result initiated complete single phase study healthy volunteer begin enrol patient cf bronchiectasis phase b study quarter cardiovascular area conduct phase clinical study darusentan treatment resistant hypertension program obtain myogen acquisition expect complete enrollment receive datum study addition research collaboration university texas novartis institute continue seek identify development candidate treatment cardiovascular disorder face numerous risk uncertaintie product candidate include list risk include challenge clinical trial protocol design ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate program pipeline complete timely basis prospect future revenue growth adversely impact total research development expense million compare million million patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent table content follow table show actual estimate expiration date united states europe primary patent patent issue pende application cover compound market product patent european patent product expiration expiration vistide hepsera letairis ambisome tamiflu macugen viread emtriva truvada atripla patent cover active pharmaceutical ingredient truvada atripla viread emtriva hepsera letairis vistide hold party acquire exclusive right patent agreement party commercial collaboration patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera application pende country asia include china relate specific form formulation hepsera asia major market therapy hepatitis b infection indication hepsera develop patent covering flolan hold party market exclusivity protection expired result generic pharmaceutical company launch generic version flolan united states obtain patent certain product year obtain marketing approval product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension example extension patent vistide grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license thirdparty technology obtain reasonable cost able obtain require license alternative technology unable develop commercialize product business adversely affect example aware body patent relate operation leap restrict distribution program design support letairis evaluate patent relevance leap patent application confidential period time patent issue know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block table content compete patent competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation reexamination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection example march public patent foundation file request reexamination united states patent trademark office pto challenge patent relate tenofovir disoproxil fumarate active ingredient truvada atripla viread pto grant request july pto issue nonfinal rejection patent step common reexamination proceeding initiate reexamination process predict ultimate outcome office action unsuccessful respond office action original claim patent narrow invalidated pto narrow invalidate patent cause similar organization seek reexamination proceeding challenge patent foreign jurisdiction pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product develop develop addition certain country africa asia include china permit enforcement patent manufacturer able sell generic version product country approval process product fda determine product grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate nda application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention discover certain case jointly own corporate partner case exclusive property difficult determine own particular invention dispute arise invention august pto adopt new rule schedule effective november october gsk successfully obtain preliminary injunction implementation rule rule include limitation number claim permit patent application number continue patent application file rule implement limit table content ability obtain broad patent coverage product product candidate allow competitor market product similar obtain patent coverage closely relate product manufacture raw material antiviral product contract party manufacture antiviral product clinical commercial purpose include truvada atripla viread emtriva hepsera vistide historically manufacture antiviral product commercial scale result acquisition raylo chemicals inc subsidiary germanybase specialty chemical company degussa ag november begin produce quantity tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient truvada atripla emtricitabine active pharmaceutical ingredient emtriva active pharmaceutical ingredient truvada atripla edmonton alberta canada facility utilize site process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational product chemical development activity improve exist commercial manufacturing process continue use multiple thirdparty contract manufacturer manufacture additional quantity tenofovir disoproxil fumarate emtricitabine manufacture adefovir dipivoxil active pharmaceutical ingredient hepsera cidofovir active pharmaceutical ingredient vistide use multiple thirdparty contract manufacturer tablet truvada atripla viread emtriva hepsera manufacturer qualify approve supply product united states european union market emtriva capsulation complete thirdparty contract manufacturer use single thirdparty manufacturer supply vistide fill package drug product truvada atripla viread emtriva hepsera finish form facilities san dimas california near dublin ireland september acquire nycome limited wholly own irish subsidiary germanybase pharmaceutical company nycome gmbh transfer certain operation dublin ireland area site facility locate cork ireland utilize site primarily solid dose tablet manufacturing certain antiviral product product packaging activity roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu future antiviral product continue consider develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future antiviral product ability conduct large scale clinical trial meet customer demand commercial product adversely affect believe technology use manufacture product proprietary antiviral product disclose necessary aspect technology contract manufacturer enable manufacture product agreement manufacturer intend restrict manufacturer reveal technology certain manufacturer comply restriction addition manufacturer develop technology relate work perform need manufacture product require enter table content additional agreement manufacturer want use technology allow manufacturer use technology manufacturer refuse allow use technology demand term use technology acceptable ambisome manufacture ambisome commercial quantity fdaapprove facility san dimas california medicines control agency united kingdom fda approve commercial production ambisome facility import ambisome european union manufacturing facility near dublin ireland perform quality control testing final labeling packaging distribution european union use commercially available material equipment manufacture product currently obtain cholesterol use manufacture ambisome single approve supplier ambisome sell freezedrie product give current projection ambisome demand believe sufficient production capacity san dimas facility meet future demand option instal additional freezedrying capacity san dimas additional requirement necessary letairis manufacture active pharmaceutical ingredient letairis exclusively edmonton alberta facility thirdparty supplier qualified active pharmaceutical ingredient letairis rely single thirdparty supplier tablet letairis flolan gsk affiliate party manufacture flolan distribution united states term distribution supply agreement gsk macugen manufacture macugen commercial quantities facilities san dimas manufacturing agreement osi pfizer currently osi provide pegaptanib sodium active pharmaceutical ingredient macugen base osis pfizer current projection macugen demand believe sufficient production capacity meet future demand seasonal operation backlog worldwide product sale reflect significant degree seasonality royalty revenue represent total revenue tamiflu royalty comprise significant portion affect seasonality royalty revenue recognize roche sale tamiflu impact severity associate flu season product delivery response avian influenza pandemic threat operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal table content food drug cosmetic act federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind application study drug candidate human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial longterm involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial fda approval process believe datum phase clinical trial adequate level safety efficacy submit appropriate filing usually form nda snda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit table content fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive postmarketing test surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include san dimas foster city facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible accelerate priority review drug treatment hiv designate use president emergency plan aid relief qualify expedite priority review viread truvada atripla receive accelerate approval priority review drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penalty drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure pricing reimbursement approval require country price reimbursement successful commercialization product depend availability governmental thirdparty payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average selling price example majority sale truvada atripla viread hepsera ambisome letairis vistide subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase pricing pressure united states internationally pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general table content legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction significant change federal medicare system recent year united states impact pricing product medicare prescription drug improvement modernization act medicare beneficiary able elect coverage prescription drug medicare prescription drug program begin january benefit initially patient transition medicaid medicare long term impact new law business clear impact depend specific decision level coverage provide therapeutic category product include term coverage provide extent preference give select product category entity provide medicare coverage attempt negotiate price concession pharmaceutical manufacturer addition discussion take place federal level pass legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer increase pressure low prescription drug price limit drug access medicare enrollee medicare patient pay coinsurance influence product recommend physician select patient result operation materially adversely affect reimbursement change emerge medicare prescription drug coverage legislation addition federal medicare proposal state medicaid drug payment change lower payment product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule additionally health care reform federal state level adversely affect payment drug time state enact health care reform legislation europe success truvada atripla viread emtriva hepsera ambisome depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month expect success product candidate particularly europe depend ability obtain reimbursement product candidate commercialize reimbursement available reimbursement policy adversely affect ability sell product profitable basis example europe international market government control price prescription pharmaceutical expect price prescription pharmaceutical decline life product volume increase new drug come market face significant price decrease product european country believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth health care fraud abuse law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law prohibit knowingly willingly present cause present payment thirdparty payor include medicare medicaid claim reimburse drug service false fraudulent claim item service provide claim claim medically unnecessary item service sale marketing activity subject scrutiny law violation fraud abuse law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid government allege convict violate law material adverse effect result operation table content november receive subpoena united states attorney office san francisco request document market medical education program truvada viread emtriva comply attorney subpoena intend cooperate relate government investigation compulsory license number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread result discussion brazilian government reach agreement brazilian health ministry reduce price viread brazil approximately addition concern cost availability tamiflu relate potential avian flu pandemic generate international discussion compulsory licensing tamiflu patent example canadian government allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop leastdevelope country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately fulltime employee believe good relation employee environment seek comply applicable statutory administrative requirement concern environmental quality continue expenditure environmental compliance protection expenditure compliance environmental law expect material effect capital expenditure result operation competitive position information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec f street ne washington dc call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically table content mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act filing available free charge request item risk factor evaluate business carefully consider follow risk addition information annual report follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale limited number product unable maintain continue increase sale hiv product result operation adversely affect currently dependent sale product treatment human immunodeficiency virus hiv infection especially truvada atripla support exist operation hiv product contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebased therapeutic fall favor unable continue increase hiv product sale result operation likely suffer likely need scale operation include spend research development rd effort hiv product sale year end december billion total revenue sales truvada atripla account respectively total hiv product sale year end december able continue growth rate sale hiv product reason state risk factor section particular follow reason hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue hiv product mature private insurer government reimburser reduce reimburse patient product increase pressure reduce price large market hiv product consist patient take hiv drug successful encourage physician change patient regimen include hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing affect substantial portion pretax income derive royalty revenue recognize sale tamiflu roche sale tamiflu decrease pretax income disproportionately affect f hoffmannla roche ltd hoffmannla roche inc roche market tamiflu worldwide treatment prevention influenza royaltypaye collaborative agreement recognize million royalty revenue year end december relate royalty table content receive fourth quarter quarter sale tamiflu roche royalty revenue represent total revenue represent pretax income period roche tamiflu sale unpredictable variability strong relationship global pandemic planning effort sale tamiflu decline sharply second half fulfillment exist pandemic stockpiling order government corporation roche recently report expect significant decrease tamiflu sale sale tamiflu decrease royalty revenue decrease pretax income decrease disproportionately decrease material fail commercialize new product expand indication exist product prospect future revenue stock price adversely affect introduce new product increase revenue exist product able increase maintain total revenue new product commercialization effort include letairis treatment pulmonary arterial hypertension pah launch united states june face risk outline section fail increase sale product bring new product market able increase revenue expand rd effort example new drug application nda submit november aztreonam lysine inhalation treatment cystic fibrosis cf marketing authorization application submit october viread treatment chronic hepatitis b united states european union grant timeline currently anticipate december committee medicinal product human use european medicine agency emea grant marketing authorization atripla european union treatment hiv infection adult virologic suppression hiv rna level copiesml current combination antiretroviral therapy month patient experience virological failure prior antiretroviral therapy know harbored virus strain mutation confer significant resistance component contain atripla restriction atriplas use european union prevent promote atripla use patient previously achieve reduction viral load use antiretroviral therapy include newly diagnose patient seek expand indication atripla european union emea require perform additional clinical trial unable complete unable expand indication atripla include broad population patient impact future sale atripla european union unknown limited market include united states restriction addition sale atripla increase expense product sale component product overall total revenue increase atripla sale increase face numerous risk uncertaintie product candidate include elvitegravir novel hiv integrase inhibitor know gs darusentan treatment resistant hypertension currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain united states food drug administration fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth adversely impact table content face significant competition face significant competition large pharmaceutical biotechnology company substantially great resource addition competitor product operate field compete long hiv product compete primarily product glaxosmithkline inc gsk market fixeddose combination product compete truvada atripla hepsera encounter increase competition baraclude entecavir bristolmyers squibb company bms tyzekasebivo telbivudine novartis pharmaceutical corporation novartis united states european union china ambisome compete primarily product produce merck co inc merck pfizer inc pfizer addition aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association letairis compete directly actelion pharmaceutical incs tracleer bosentan indirectly pah product united therapeutics corporation pfizer aztreonam lysine inhalation treatment cf approve marketing compete tobi tobramycin inhalation market novartis viread treatment hepatitis b virus approve marketing compete hepsera current product treatment chronic hepatitis b hepsera baraclude entecavir tyzekasebivo telbivudine significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case limit post approval use product long period time patient take numerous medicine underlie health problem expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product safety efficacy study viread emtriva dose separate product ongoing underway long period time safety efficacy study truvada viread emtriva underway conduct similar study atripla truvada sustiva addition product letairis approve fda june member new class compound call endothelin receptor antagonist pose specific risk include risk liver injury birth defect risk letairis available letairis education access program leap restrict distribution program intend help physician patient learn risk associate product assure appropriate use product product additional patient discover new risk associate letairis result change distribution program additional restriction use letairis decrease demand product example launch letairis case edema certain patient take letairis report information recently add product label negatively impact demand product safety resistance drug interaction issue arise market product sale product limit halt regulatory authority operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis achieve continued compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda comparable regulatory agency country continue clinical trial truvada atripla viread emtriva hepsera ambisome letairis table content currently approve additional use anticipate file marketing approval additional country additional product year product fail receive marketing approval timely basis addition market product manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution september president bush sign law food drug administration amendment act fdaaa create significant addition fdas authority fdaaa expand fdas authority thing require sponsor market product conduct postapproval clinical study assess know risk signal risk identify unexpected risk mandate labeling change product point product lifecycle base new safety information require sponsor implement risk evaluation mitigation strategy product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply new requirement impose sponsor fda result significant civil monetary penalty result anticipate timeline clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt example observe possible qt prolongation measure cardiovascular safety phase ab study novel nonnucleoside polymerase inhibitor know gs result conduct pilot qt study healthy volunteer mg mg bid dose qt prolongation confirm mg dose prolongation mg dose small believe clinically manageable seek fdas consent reinitiate dose hcvinfecte individual define efficacy safety compound delay development compound unable obtain fda consent reinitiate dose program delay decide cease effort commercialize compound addition face challenge clinical trial protocol design example discussion fda european medicine evaluation agency concern design phase clinical study elvitegravir novel hiv integrase inhibitor know gs result discussion positive clinical trial elvitegravir complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business table content reliance thirdparty contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent thirdparty contract research organization cro control perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely impact february advise fda discover certain irregularity inspection bioanalytical analysis conduct organization thirdparty cro period review cro perform bioanalytical analysis study certain product know investigation involve impact clinical datum result relate regulatory approval manufacturing problem delay product shipment regulatory approval adversely affect result operation depend party perform manufacturing activity effectively timely basis truvada atripla viread emtriva hepsera letairis vistide addition roche party responsible manufacturing tamiflu manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer subject fda current good manufacturing practice gmp extensive regulation govern manufacturing process stability testing recordkeeping quality standard similar regulation effect country manufacture operation subject routine inspection regulatory agency additionally thirdparty manufacturer independent entity subject unique operational financial risk control thirdparty manufacturer fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect ability successfully manufacture commercialize aztreonam lysine inhalation approve depend ability continue manufacture multiproduct facility aztreonam lysine monobactam gramnegative antibiotic currently plan manufacture party multiproduct manufacturing facility historically fda permit manufacture monobactam multiproduct manufacturing facility assurance fda continue allow practice currently singleproduct facility dedicated manufacture aztreonam lysine inhalation engage contract manufacturer singleproduct facility aztreonam lysine inhalation fda prohibit manufacture monobactam antibiotic like aztreonam lysine inhalation multiproduct manufacturing facility future able procure singleproduct manufacturing facility timely manner adversely affect commercial supply aztreonam lysine inhalation anticipate financial result attributable product approve able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial inability obtain material timely manner delay development effort product candidate limit ability generate revenue table content supplier key component material name nda file fda product candidate significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility example manufacture ambisome fill finish macugen exclusively facilities san dimas california event natural disaster include earthquake equipment failure strike difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome macugen meet market need addition depend single supplier high quality cholesterol manufacture ambisome depend single supplier active pharmaceutical ingredient tablete letairis product candidate aztreonam lysine inhalation pende fda approval administer lung patient device single supplier single site plan seek fda approval manufacture aztreonam lysine inhalation facility san dimas currently rely single thirdparty supplier manufacture aztreonam lysine inhalation guarantee fda approve facility manufacture aztreonam lysine inhalation timely manner addition aware thirdparty supplier gmp compliance issue result issuance approvable letter fda company supplier manufacture approvable letter indicate fda prepare approve nda satisfaction certain specify condition include resolution gmp compliance issue supplier supplier unable resolve gmp compliance issue receive approvable letter require resolution compliance issue condition obtain marketing approval product compliance issue resolve timely manner able obtain fda approval manufacture aztreonam lysine inhalation facility san dimas timely manner aztreonam lysine inhalation approve anticipate timeframe anticipate sale drug negatively impact problem single supplier depend negatively impact development commercialization effort depend relationship company sale marketing performance revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration bms atripla united states europe canada japan tobacco inc viread truvada emtriva japan gsk hepsera outside united states astellas pharma inc ambisome united states canada dainippon sumitomo pharma co ltd ambisome japan pfizer vistide roche tamiflu osi pharmaceuticals inc pfizer macugen country rely international distributor sale truvada viread emtriva hepsera ambisome relationship involve clinical development product partner reliance collaborative relationship pose number risk include inability control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor table content corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan south korea success hepsera territory depend entirely effort gsk regard gsk promote epivirhbvzeffix product compete hepsera consequently gsk marketing strategy hepsera influence promotion epivirhbvzeffix receive royalty gsk equal percentage gsk net sale hepsera net sale gsk epivirhbvzeffix gsk fail devote sufficient resource succeed develop commercialize hepsera territory potential revenue sale hepsera territory substantially reduce addition letairis distribute thirdparty specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling use specialty pharmacy require significant coordination sale marketing medical affair regulatory affair legal finance organization involve risk include limited risk specialty pharmacy provide accurate timely information inventory patient data safety complaint effectively sell support letairis devote resource necessary sell letairis volume time frame expect able satisfy financial obligation cease operation rely party administer leap restrict distribution program design support letairis party provide information education prescriber patient risk letairis confirm insurance coverage investigate alternative source reimbursement assistance ensure fulfillment risk management requirement mandate letairis fda coordinates control dispense patient thirdparty specialty pharmacy failure party specialty pharmacy distribute letairis perform expect result regulatory action fda decrease letairis sale harm business dependent supplier inhalation device deliver aztreonam lysine inhalation regulatory approval obtain distribute device specialty pharmacy distribution channel control key aspect relate device example supplier encounter issue regulatory agency relate device unable supply sufficient quantity device time commercial launch follow launch issue cause delay commercial launch aztreonam lysine inhalation able realize anticipate contribution aztreonam lysine inhalation financial result table content expense associate clinical trial cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval expensive difficult accurately predict control timing expense quarter quarter uneven unexpected spending program cause operating result fluctuate quarter quarter sale fluctuation result inventory level hold wholesaler parallel importation difficult accurately forecast sale cause earning fluctuate adversely affect stock price estimate future demand product consider shelf life inventory regularly review realizability inventory actual demand estimate demand require record inventory writedown adverse impact result operation example result review inventory realizability fourth quarter record writedown portion gilead access program inventory year end december approximately product sale united states wholesaler cardinal health inc mckesson corp amerisourcebergen corp inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand wholesaler enter inventory management agreement completely effective match inventory level end user demand estimate determine end user demand nonretail sector united states include government institution include state aids drug assistance program correctional facility large health maintenance organization contribute approximately sale hiv product united states december tend consistent term buy pattern cause quarter quarter fluctuation necessarily mirror purchasing pattern see retail sector european union require permit product purchase country sell country allow buyer country governmentapprove price product relatively high purchase product country price product relatively low purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter difficult forecast addition wholesaler attempt arbitrage pricing differential country purchase excessive quantity product activity result fluctuate quarterly sale certain country reflect actual demand product customer quarterly fluctuation impact earning adversely affect stock price example experience increase sale hiv product france believe portion product reexporte country resold high price sale truvada viread france country sale reexporte continue fluctuate activity continue france european country result operation adversely affect success depend significant degree ability protect patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right table content preserve trade secret operate infringe proprietary right properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent addition competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful addition time time certain individual entity challenge patent example march public patent foundation file request reexamination united states patent trademark office pto challenge patent relate tenofovir disoproxil fumarate active ingredient truvada atripla viread pto grant request july pto issue nonfinal rejection patent step common reexamination proceeding initiate reexamination process predict ultimate outcome office action unsuccessful respond office action original claim patent narrow invalidated pto narrow invalidate patent cause similar organization seek examination proceeding challenge patent foreign jurisdiction patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapy hepatitis b infection indication hepsera develop flolan patent market exclusivity protection expired result generic pharmaceutical company launch generic version flolan united states obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension approval process product fda determine product grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate nda application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully august pto adopt new rule schedule effective november october gsk successfully obtain preliminary injunction implementation table content rule rule include limitation number claim permit patent application number continue patent application file rule implement limit ability obtain broad patent coverage product product candidate allow competitor market product similar obtain patent coverage closely relate product success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation leap restrict distribution program design support letairis evaluate patent relevance leap addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor significant portion product sale occur outside united states currency fluctuation cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro use foreign currency forward option contract hedge percentage forecast international sale primarily denominate euro hedge portion account receivable balance denominate foreign currency reduce eliminate exposure currency fluctuation date sale record date cash collect dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business net foreign currency exchange impact pretax earning include revenue expense generate outside united states impact hedging activity favorable million compare hedge program hedge portion total exposure significant foreign exchange rate fluctuation short period time adversely affect result operation face credit risk european customer adversely affect result operation european product sale governmentowne support customer greece italy portugal spain subject significant payment delay government funding reimbursement practice account receivable governmentowne support customer country total approximately million december historically receivable accumulate period time settle large lump sum payment government funding available significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect table content product revenue gross margin reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available substantially reduce price country participate gilead access program atripla merck distribute substantially reduce price hivinfecte patient develop country august agreement revenue adversely affect addition establish partnership indian generic manufacturer distribute highquality lowcost generic version tenofovir disoproxil fumarate develop world country include india generic version medication license reexporte united states europe market outside country revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter year end december observe increase crossborder sale european union require permit crossborder sale consumer able purchase product include hiv product internet pharmacy country substantial discount crossborder sale adversely affect revenue gross margin country require grant compulsory license product face generic competition product number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread result discussion brazilian government reach agreement brazilian health ministry reduce price viread brazil approximately addition concern cost availability tamiflu relate potential avian flu pandemic generate international discussion compulsory licensing tamiflu patent example canadian government allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop leastdevelope country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale table content exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average sale price example majority sale truvada atripla viread hepsera ambisome vistide letairis subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase pricing pressure united states internationally pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general europe success truvada atripla viread emtriva hepsera ambisome tamiflu depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month expect success product candidate particularly europe depend ability obtain reimbursement product candidate commercialize reimbursement available reimbursement policy adversely affect ability sell product profitable basis example europe international market government control price prescription pharmaceutical expect price prescription pharmaceutical decline life product volume increase new drug come market face significant price decrease product european country believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth result operation adversely affect current future health care reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction significant change federal medicare system recent year united states impact pricing product medicare prescription drug improvement modernization act medicare beneficiary able elect coverage prescription drug medicare prescription drug program begin january benefit initially patient transition medicaid medicare long term impact new law business clear impact depend specific decision level coverage provide therapeutic category product include term coverage provide extent preference give select product category entity provide medicare coverage attempt negotiate price concession pharmaceutical manufacturer addition discussion take place federal level pass legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer increase pressure low prescription drug price limit drug access medicare enrollee medicare patient pay coinsurance influence product recommend physician select patient result operation materially adversely affect reimbursement change emerge medicare prescription drug coverage legislation addition federal medicare proposal state medicaid drug payment change lower payment product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule additionally health care reform federal state level adversely affect payment drug time state enact health care reform legislation table content face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company recent year coverage availability product liability insurance decrease cost defend lawsuit pay damage product liability claim exceed coverage impair financial condition ability clinically test product candidate market product addition claim regardless merit impair financial condition future demand product assumption determine selfinsurance level wrong materially impact business continually evaluate level selfinsurance base historical claim experience demographic factor severity factor actuarial assumption future occurrence claim differ assumption historical trend result operation business cash flow financial condition materially impact claim expense expensive litigation government investigation reduce earning certain officer officer name defendant class action lawsuit allege violation federal security law lawsuit dismiss court plaintiff appeal dismissal november receive subpoena attorney office san francisco request document market medical education program truvada viread emtriva comply attorney subpoena intend cooperate relate government investigation outcome lawsuit lawsuit bring investigation investigation bring inherently uncertain adverse development outcome result significant monetary damage penalty injunctive relief significantly reduce earning cash flow change effective income tax rate reduce earning factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate account stock option sharebase payment merger acquisition future level rd spending change accounting standard future level capital expenditure changes mix earning tax jurisdiction operate change overall level pretax earning finalization federal state foreign income tax audits impact income tax provision result abovementione factor significant negative impact net income income tax return audit federal state foreign tax authority currently examination internal revenue service tax year franchise tax board california tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction adverse resolution exposure report period material impact result operation period change accounting affect financial position result operation generally accept accounting principle relate implementation guideline interpretation highly complex involve subjective judgment change rule interpretation adoption new pronouncement application exist pronouncement change business significantly affect financial position result operation table content example august fasb issue comment propose financial accounting standard board fasb staff position fsp apb accounting convertible debt instrument settle cash conversion include partial cash settlement fsp apb propose fsp apb address instrument commonly refer instrument c eitf issue convertible bond issuer option settle cash conversion require issuer settle principal cash conversion spread cash net share issuer option propose fsp apb require bifurcation conversion option debt instrument classification conversion option equity accretion result discount debt result additional interest expense report income statement november expiration initial comment period fasb announce begin redeliberation guidance propose fsp january final guidance issue predict ultimate outcome include final guidance effective believe fasb determines account instrument c security manner describe accounting convertible senior note affect change presentation balance sheet adverse impact result operation material fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm item b unresolved staff comment applicable item property corporate headquarters include principal office commercial administrative research development rd facility locate foster city california location building lease facility san dimas california house manufacturing warehousing rd activity addition lease facility durham north carolina westminster colorado seattle washington house administrative rd activity european headquarter include commercial medical administrative facility locate london area united kingdom lease facility dublin area ireland house manufacturing distribution activity acquire manufacturing facility cork ireland september connection acquisition nycome limited transfer certain operation dublin area site facility utilize site primarily solid dose tablet manufacturing antiviral product product packaging activity manufacture facility edmonton alberta canada use conduct process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product chemical development activity improve exist commercial manufacturing process table content addition lease additional facility house commercial medical administrative activity australia austria belgium canada france germany greece italy netherlands portugal spain sweden switzerland turkey united kingdom believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet longterm growth need item legal proceeding information pertain legal proceeding find head legal proceeding item note commitment contingency consolidate financial statement page annual report incorporate reference item submission matter vote security holder matter submit vote security holder quarter end december table content ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq global select market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception currently expect retain earning use operation expansion business anticipate pay cash dividend near future table content performance graph follow graph compare total stockholder return past year index standard poor stock index label sp index nasdaq biotechnology index label nasdaq biotechnology index nasdaq crsp total return index nasdaq global select market company label nasdaq index nasdaq pharmaceutical index label nasdaq pharmaceutical index total return index assume reinvestment dividend pay company include index calculate december year composite member sp index nasdaq biotechnology index intend use indice comparator stock performance purpose follow graph go forward composite member sp index require applicable regulation use index comparator believe nasdaq biotechnology index relevant comparator compose peer company linesof business similar stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nasdaq biotechnology sp nasdaq nasdaq pharmaceutical index december table content issuer purchase equity securities october board director authorize program repurchase common stock billion open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated share repurchase transaction similar arrangement stock repurchase program expire december table summarize stock repurchase activity month end december thousands share amount maximum total number fair value share total number share purchase share average price publicly purchase purchase pay share announce programs program october october november november december december total difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation table content item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue purchase inprocess research development total cost expense income loss operation gain warrant provision benefit income taxis net income loss net income loss sharebasic share share calculationbasic net income loss sharedilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible debt retain earning accumulate deficit otal stockholder equity complete acquisition nycome limited aggregate purchase price million allocate primarily property plant equipment complete acquisition myogen inc aggregate purchase price billion billion allocate purchase inprocess research development iprd million allocate defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization million allocate table content gilead sciences inc select consolidated financial datacontinue goodwill million allocate net tangible asset acquire net asset corus pharma inc million million allocate purchase iprd million allocate net defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization million allocate net tangible asset million allocate assemble workforce recognize million royalty revenue relate resolution dispute f hoffmannla roche ltd hoffmannla roche inc roche record tax provision benefit million relate repatriation qualified foreign earning american job creation act ajca record gain million relate warrant purchase capital stock eyetech pharmaceuticals inc predecessor osi pharmaceuticals inc complete initial public offering complete acquisition net asset triangle pharmaceuticals inc aggregate purchase price million approximately million purchase price allocate purchase iprd record income tax benefit million relate reduction valuation allowance certain net defer tax asset adopt statement financial accounting standard revise sharebased payment modify prospective basis begin january note consolidated financial statement september june implement twoforone stock split form stock dividend share share amount period present restate reflect stock split issue billion principal convertible senior note private placement enter uncollateralized million term loan agreement facilitate cash dividend distribution repatriation qualified foreign earning provision ajca cash dividend declare pay common stock table content item management discussion analysis financial condition result operation follow management discussion analysis mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar executive summary past year mark th anniversary founding gilead achievement important milestone continue discover develop commercialize innovative therapeutic area unmet medical need grow product sale significantly execute product approval launch multiple territory inlicense new compound research pipeline progress product candidate clinic integrate multiple site acquire continued strengthen worldwide organization infrastructure operating result lead product sale billion hiv product sale truvada atripla viread emtriva billion increase key driver total product sale growth compare total product sale truvada increase million compare prior year despite availability atripla united states july atripla product sale increase million truvada atripla sale comprise total product sale addition commercial progress success atripla united states partner bristolmyers squibb company bm expand atripla collaboration include country comprise european union norway iceland december receive approval european commission market sell atripla european territory begin ship atripla germany united kingdom austria expect launch product remainder european union pricing sale marketing matter finalize approve atripla continues comprise large proportion total product sale expect product gross margin continue decrease decrease result inclusion bmss sustiva efavirenz carry zero gross margin product sale cost good atripla product gross margin decrease high percentage atripla mix product sale compare hepsera product sale increase drive primarily sale volume growth major geographical region favorable foreign currency exchange environment ambisome product sale increase drive primarily sale volume growth europe impact favorable foreign currency exchange environment depreciation dollar major european currency foreign currency denominate product sale experience net benefit foreign currency fluctuation consider impact hedging activity result foreign currency favorable impact approximately million pretax income compare addition growth product sale royalty revenue increase compare million royalty revenue recognize million record royalty sale tamiflu f hoffmannla roche ltd hoffmannla roche inc roche strong sale tamiflu roche include sale tamiflu relate worldwide pandemic planning initiative contribute increase royalty revenue despite high royalty recognize roche recently announce expect marked decline tamiflu sale relate pandemic planning expect decline significantly reduce royalty receive sale tamiflu adversely impact financial result table content june letairis ambrisentan product acquire acquisition myogen inc myogen approve food drug administration fda treatment pulmonary arterial hypertension pah october file supplemental new drug application nda fda type ii variation european medicine evaluation agency emea marketing approval viread treatment chronic hepatitis b adult additionally november submit nda fda marketing approval aztreonam lysine inhalation treatment pulmonary pseudomona aeruginosa p aeruginosa infection people cystic fibrosis cf regulatory filing relation viread hepatitis b aztreonam lysine inhalation cf progress development compound drug candidate inlicense collaboration partner include hiv area complete phase clinical trial elvitegravir gs novel integrase inhibitor hiv license japan tobacco inc integrase inhibitor represent new way attack hiv potential treatment alternative patient develop resistance exist class therapy pende positive outcome discussion fda emea concern design phase program anticipate dose patient phase clinical study elvitegravir hepatitis b area file supplemental nda fda type ii variation emea marketing approval viread treatment chronic hepatitis b adult application base datum obtain key pivotal phase study complete year anticipate decision emea fda second quarter respectively hepatitis c area present preliminary datum november lead compound hepatitis c virus gs nonnucleoside polymerase inhibitor investigate qt prolongation certain dose pende fda consent plan reinitiate phase ab study gs define efficacy safety compound year enter exclusive license agreement lg life sciences ltd lgls develop commercialize certain caspase inhibitor treatment fibrotic disease caspase inhibitor show potential treatment chronic hepatitis c disease characterize tissue scar fibrosis agreement grant commercialization right lglss investigational caspase inhibitor include gs evaluate ongoing phase clinical trial potential treatment chronic hepatitis c anticipate datum end relate collaboration pay million upfront license fee record research development rd expense cardiovascular area plan continue enroll phase clinical study darusentan treatment resistant hypertension expect complete enrollment addition letairis pah approve united states june partner glaxosmithkline inc gsk right ambrisentan territory outside united states receive positive opinion european committee human medicinal product treatment pah february approve gsk market ambrisentan volibris respiratory area present datum second pivotal study aztreonam lysine inhalation inhale antibiotic treatment patient cf pulmonary infection p aeruginosa nda file fda november plan submit marketing authorization application emea second quarter respiratory area complete phase study healthy volunteer gs proprietary formulation combination tobramycin fosfomycin inhalation begin enrol patient phase b clinical study additionally august enter research collaboration license agreement parion sciences inc parion research develop commercialize certain epithelial sodium channel inhibitor treatment pulmonary disease connection collaboration pay million upfront license fee record rd expense million investment parion table content take program contribute increase rd expense compare expect research clinical activity area continue increase rd expense addition commercial clinical effort continue expand worldwide organization infrastructure integrate site acquire acquisition corus pharma inc corus myogen raylo chemicals inc september acquire integrate nycome limited cork ireland base manufacturing tableting operation transfer certain exist dublin operation nycome facility cork utilize cork facility solid dose tablet manufacturing certain antiviral product product packaging activity strategy well build manage expand presence new exist market internationally establish new subsidiary turkey austria switzerland process establish marketing subsidiary belgium denmark finland netherlands norway sweden initiative believe help reduce reliance thirdparty distributor contribute increase sell general administrative sga expense continue increase headcount expand marketing promotional activity country continue increase sga expense continue expand internationally launch product new territory include atripla european territory strong operating result contribute operate cash flow billion help fund rd activity corporate development opportunity worldwide infrastructure capital requirement daily operating need additionally strong cash position allow repurchase million common stock repurchase complete billion stock repurchase program initiate allow initiate billion stock repurchase program october addition enter amend restate credit agreement credit facility increase billion provide great access fund future requirement arise plan expand international footprint advance additional drug candidate clinic launch viread hepatitis b aztreonam lysine inhalation cf approve strengthen relationship corporate partner continue priority especially bms continue launch atripla european territory finally plan continue strengthen worldwide infrastructure well support grow employee customer base well facilitate expand manufacture research development commercial activity critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition allowance doubtful account inventory prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience marketspecific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement table content revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure record estimate reduction revenue government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product estimate deduct gross product sale time revenue recognize reduction gross product sale government rebate significantly impact report net product sale base certain estimate require complex significant judgment management government rebate estimate amount payable governmentmanage medicaid program certain qualify federal state foreign government program reimbursement portion retail price prescription fill cover program government rebate invoice directly record accrue liability consolidate balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low price record allowance account receivable estimate sale allowance base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program product sale channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate million million million respectively represent total gross product sale respectively deduct gross product sale base current information available actual government rebate claim period vary estimate record period december accrue government rebate million million respectively accrue liability allowance million million respectively record account receivable follow table summarize aggregate activity accrue government rebate allowance accrue liability account balance deduct balance begin charge end year expense accrual year year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total table content allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require allowance doubtful account balance percentage total account receivable materially change december december believe allowance doubtful account adequate cover anticipate loss current condition significant deterioration factor especially respect government funding reimbursement practice european market materially change expectation result increase allowance doubtful account inventory record writedown value inventory base review bad batch experience manufacturing process quality control review inventory generally record inventory write down relate estimate obsolescence risk competition primarily shelf life product long current assumption future production inventory level demand competition change actual market condition favorable project management additional inventory writedown require negatively impact product gross margin result operation prepay royalty capitalize royalty prepay cost specifically related emtricitabine royalty pay emory university emory hiv indication base present value future royalty obligation expect pay emory assume certain expect future level product sale incorporate emtricitabine present value future royalty obligation derive weighted average cost capital review quarterly expect future sale level product indicator require writedown net recoverable value asset change estimate life prepay royalty potential indicator impairment include launch significant product competitor significant deviation recognize product sale compare forecast product safety issue recall amortize prepay royalty base effective royalty rate derive forecast hiv product sale incorporate emtricitabine product sale forecast prepare annually determine good estimate future activity consider factor historical expect future patient usage uptake product introduction complimentary combination therapie product future product launch plan previously unanticipate significant change occur sale forecast include introduction compete product competitor hiv market emtricitabine prospectively update royalty rate amortize prepay royalty increase future royalty expense december prepay royalty asset relate emtricitabine royalty pay emory million amortization expense relate prepay royalty asset million million million year end december respectively clinical trial accrual record accrual estimate clinical study cost clinical study perform thirdparty contract research organization cro cost significant component rd expense incur cro cost million million million respectively table content accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro validate accrual quarterly vendor perform detailed review activity relate significant contract base result validation process assess appropriateness accrual adjustment deem necessary ensure expense reflect actual effort incur cro generally significant portion total clinical trial cost associate start activity trial patient enrollment extensively outsource clinical trial activity usually perform small portion startup activity inhouse result cro typically perform total startup activity trial include document preparation site identification screen preparation prestudy visit training program management general cost typically total cro contract value actual basis percentage range significantly wider contract expand reduced scope compare original budget startup cost usually occur month contract execute milestone eventdriven nature remain activity relate cost patient monitor administration generally occur ratably life individual contract study contract negotiate fix unit price vary length month single dose phase study year complex phase clinical study average length contract upper end range order provide longterm safety efficacy datum support commercial launch truvada viread atripla emtriva hepsera letairis material cro contract terminable write notice generally liable actual effort expend cro certain noncancelable expense incur point termination amount pay advance relate uncompleted service refund contract terminate contract include additional termination payment payable terminate contract additional termination payment record probable contract terminate december difference actual estimate activity level particular study material management receive complete accurate information vendor underestimate activity level associate study give point time record additional potentially significant rd expense future period tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination adjustment determined likely certain defer tax asset realized release related valuation allowance result income tax benefit approximately million million respectively future effective income tax rate affect factor change tax law regulation rate change interpretation exist law regulation impact accounting stockbase compensation change international organization change overall level income tax june financial accounting standard board fasb issue fasb interpretation accounting uncertainty income taxis fin interpretation statement financial accounting table content standard sfas accounting income taxis sfas fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return fin provide guidance derecognition classification interest penalty account interim period disclosure transition january adopt fin increase liability unrecognized tax benefit million corresponding charge opening balance accumulate deficit permit fin addition reclassify million unrecognized tax benefit shortterm income taxis payable noncurrent defer tax asset longterm income taxis payable date adoption total federal state foreign unrecognized tax benefit million record primarily longterm income taxis payable consolidated balance sheet include accrue liability relate interest million total unrecognized tax benefit january million recognize reduce effective tax rate period recognition permit provision fin continue classify interest penalty relate unrecognized tax benefit income tax provision consolidated statement operation december total federal state foreign unrecognized tax benefit million include interest million total unrecognized tax benefit million recognize reduce effective tax rate period recognition respect unrecognized tax benefit currently unable reasonably reliable estimate period cash settlement respective tax authority file federal state foreign income tax return jurisdiction unite states abroad federal california income tax purpose statute limitation remain open year inception utilization net operating loss relate prior year income tax return audit federal state foreign tax authority currently examination internal revenue service tax year franchise tax board california tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction believe position comply applicable law periodically evaluate exposure associate tax filing position record liability relate uncertain tax position base fin believe item currently pende material adverse effect consolidated financial statement adverse resolution item period material impact result operation period prior adoption fin record liability relate uncertain tax position base sfas accounting contingency stockbase compensation december fasb issue sfas revise sharebased payment sfas r require sharebase payment employee director include grant stock option recognize statement operation base fair value sfas r supersede accounting principle board opinion accounting stock issue employee apb amend sfas statement cash flow january adopt sfas r modify prospective method adoption permit sfas r require compensation expense record nonveste stock option stockbase award begin quarter adoption accordance modify prospective method prior period amount restate reflect provision sfas r table content prior adoption sfas r accordance provision sfas elect follow apb fasb interpretation account certain transaction involve stock compensationan interpretation apb opinion accounting employee stockbase plan apb exercise price employee director stock option equal great fair value underlie stock date grant compensation expense recognize require sfas pro forma impact expense fair value stock option employee stock purchase plan disclose note consolidated financial statement connection adoption sfas r refined valuation assumption methodology derive assumption elect continue blackschole option valuation model fair value stock option grant prior adoption sfas r calculate multiple option approach fair value stock option grant begin january calculate single option approach concurrent adoption sfas r determined blend historical volatility imply volatility trade option stock well measure market condition expect volatility previously historical stock price volatility reliable source volatility datum estimate weightedaverage expect life stock option base historical cancellation exercise datum relate stock option contractual term vest term award record stockbase compensation expense grade vest expense attribution approach nonveste stock option grant prior adoption sfas r consistent expense attribution approach historical sfas disclosure straightline expense attribution approach stock option grant adoption sfas r currently believe straightline expense attribution approach well reflect level service provide vest period award stockbase compensation expense relate stock option recognize net estimate forfeiture estimate forfeiture base historical experience result adoption sfas r recognize tax benefit stockbase compensation additional paidincapital apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement operation apic year end december recognize stockbase compensation expense million million respectively operating expense capitalize million million respectively inventory december unrecognize stockbase compensation million relate nonveste stock option expect expense estimate weightedaverage period year management discuss development selection disclosure critical accounting policy audit committee board director audit committee review disclosure present relate result operation total revenue total revenue billion billion billion include total revenue product sale royalty revenue contract revenue table content product sale product sale year consist follow thousand change change hiv product truvada atripla viread emtriva total hiv product hepsera ambisome total product sale total product sale increase compare primarily increase total product sale volume billion favorable foreign currency exchange impact million total product sale increase compare primarily increase total product sale volume million significant percentage product sale continue denominate foreign currency forward option contract hedge percentage forecast international sale primarily denominate euro reduce eliminate fluctuation sale change foreign currency exchange rate hiv product hiv product sale increase compare compare primarily drive product sale volume growth average selling price hiv product increase compare primarily drive higher overall selling price hiv product transition patient united states coverage medicaid medicare generally reimburse high rate estimate benefit net product sale result transition approximately million truvada truvada sale increase compare compare case primarily drive strong sale volume growth europe favorable foreign currency exchange environment truvada sale account total hiv product sale respectively atripla atripla sale increase compare primarily year atripla sale continue strong uptake atripla united states consolidate atripla product sale primary beneficiary joint venture bms united states efavirenz portion atripla sale approximately million million respectively atripla approve sale united states july european union december atripla sale account total hiv product sale sale atripla european union significant viread viread sale decrease compare compare case primarily low sale volume united states europe drive impact table content patient switch vireadcontaine regimen contain truvada andor atripla country truvada andor atripla available partially offset sale volume increase latin america favorable foreign currency exchange environment viread sale decrease compare partially offset favorable foreign currency exchange environment emtriva emtriva sale decrease compare compare decrease year primarily overall sale volume decrease drive impact patient switch emtrivacontaine regimen contain truvada andor atripla country product available hepsera hepsera sale increase compare primarily drive sale volume growth major geographical region product sell favorable foreign currency exchange environment hepsera sale increase compare primarily drive sale volume growth united states europe hepsera sale volume increase respect sale hepsera gsk sell hepsera gsk manufacturing cost connection gsk distribution activity asia collect royalty gsk sale hepsera customer record royalty revenue ambisome sale ambisome increase compare primarily sale volume growth europe favorable foreign currency exchange impact sale ambisome increase percent compare primarily sale volume growth region partially offset low pricing region ambisome product sale united states relate solely sale ambisome astellas pharma inc record manufacturing cost expect total product sale continue grow continue expand sale marketing effort royalty revenue follow table summarize period period change royalty revenue thousand change change royalty revenue significant source royalty revenue sale tamiflu roche royalty revenue million increase compare million increase compare increase comparative period primarily drive recognition tamiflu royalty roche million million respectively increase tamiflu royalty comparative period high tamiflu sale record roche include sale relate pandemic planning initiative worldwide increase tamiflu royalty compare elimination contractual cost good adjustment result dispute resolution november historically reduce tamiflu royalty recognize prior november recognize royalty tamiflu sale roche quarter follow quarter sell table content november resolve dispute roche relate development license agreement agree terminate relate arbitration pende roche relate dispute resolution roche pay million recognize payment royalty revenue payment consist million relate dispute royalty million relate reimbursement contractual cost good adjustment previously reduce earn royalty million relate update royalty payable month base thencurrent royalty rate instead prior year effective royalty rate roche report january expect significant decrease tamiflu sale compare expect royalty revenue significantly lower compare cost good sell product gross margin follow table summarize period period change product sale thousand cost good sell thousand product gross margin change change total product sale cost good sell product gross margin product gross margin compare primarily product mix change especially atripla low product gross margin comprise large proportion product sale product gross margin compare low gross margin compare primarily launch atripla united states million writedown inventory gilead access program estimate net realizable value product mix change patient continue switch viread high margin product truvada andor atripla low gross margin compare partially offset low effective royalty rate result july emtricitabine royalty buyout discuss lower active pharmaceutical ingredient cost high average selling price hiv product united states atripla product sale decrease product gross margin correspond impact product gross profit primary beneficiary joint venture bms united states consolidate atripla product sale benefit product gross margin truvada portion atripla efavirenz portion atripla product sale carry zero product gross profit gross margin joint venture purchase efavirenz bms bmss average net selling price efavirenz united states prior july pay royalty emory worldwide net sale product contain emtricitabine july royalty pharma purchase respectively royalty interest own emory exchange elimination royalty obligation result purchase capitalize million prepay royalty represent share million purchase price quarter begin amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast sale product contain emtricitabine record royalties royalty pharma base actual emtricitabine net sale relative royalty pharma ownership interest underlie emory royalty interest expect product gross margin lower compare primarily high mix atripla product sale include efavirenz portion atripla product sale zero product gross profit partially offset product gross margin improvement drive lower active pharmaceutical ingredient cost table content research development expense follow table summarize period period change major component rd expense year thousand change change research clinical development pharmaceutical development total research development rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform cro material supplies license fee overhead allocation consist support facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost phase clinical trial pharmaceutical development expense consist cost product formulation chemical analysis rd expense increase million compare primarily increase compensation benefit expense million largely high headcount increase clinical study expense million increase contract service expense million relate clinical product development research activity cardiovascular program addition pay million upfront license fee lgl million license relate fee pari gmbh pari expense future alternative use technology rd expense increase million compare primarily increase compensation benefit expense million largely high headcount include stockbase compensation expense million adoption sfas r january increase contract service clinical study expense million relate clinical product development research activity hiv hepatitis program respiratory cardiovascular program assume acquisition myogen corus high expense partially offset low milestone payment japan tobacco inc japan tobacco compare related licensing development elvitegravir lead integrase inhibitor candidate know gs million payment emory connection amendment license agreement emory relate obligation develop emtricitabine hepatitis b indication general significant collaboration payment like lgls pari japan tobacco emory cause rd expense fluctuate period period expect rd expense increase level increase spending internal collaborative rd effort relate progress product candidate advance clinical study continuation clinical trial relate elvitegravir hiv darusentan resistant hypertension viread hbv initiation phase program letairis sell general administrative expense follow table summarize period period change sga expense year thousand change change sell general administrative table content sga expense increase million compare increase primarily increase compensation benefit expense million largely high headcount increase market promotional expense million antiviral cardiovascular area include related launch letairis treatment pah sga expense increase million compare high expense primarily drive high headcount increase compensation benefit million include stockbase compensation expense million adoption sfas r january increase expense million contract service promotional program relate business growth business development activity preparation launch atripla united states million writeoff certain capital asset relate renovations corporate headquarter campus expect sga expense increase primarily high cost incur administrative activity sale marketing effort support business growth cost associate anticipate launch atripla european union viread hbv united states european union aztreonam lysine inhalation cf united states purchase inprocess research development expense connection acquisition myogen corus record purchase inprocess research development iprd expense billion million respectively year end december purchase iprd expense myogen represent estimate fair value myogen incomplete rd program reach technological feasibility alternative future use acquisition date expense acquisition summary program acquisition date update subsequent change status development follow estimate acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic acidclass endothelin phase clinical trial complete prior acquisition date file receptor antagonist era treatment pah nda fda december june fda approve letairis ambrisentan treatment pah united states additionally march emea validate marketing authorization application ambrisentan treatment pah file collaboration partner gsk february ambrisentan receive positive opinion european committee human medicinal product treatment pah market volibris gsk approval darusentan orally active etaselective era treatment resistant phase clinical development acquisition date date hypertension filing table content estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate fair value purchase iprd present value discount rate base estimate internal rate return myogen operation comparable estimate weighted average cost capital company myogen profile represent rate market participant use value purchase iprd compensate differ phase development ambrisentan darusentan probabilityadjuste estimation expect future cash flow associate program determine time present value expect future cash flow discount rate project cash flow ambrisentan darusentan program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market purpose estimate fair value ambrisentan program estimate program approximately complete acquisition date base estimate time cost complete phase clinical trial complete acquisition date estimate incur future rd cost approximately million million date acquisition include year commercialization expect occur material net cash inflow estimate begin ambrisentan assume necessary regulatory approval received product successfully commercialize date purpose estimate fair value darusentan program estimate program approximately complete acquisition date base estimate time cost complete remain effort include completion phase clinical development prepare filing nda fda acquisition date estimate incur future rd cost approximately million million date acquisition include year commercialization expect occur material net cash inflow estimate begin darusentan assume necessary regulatory approval received product successfully commercialize date remain effort complete darusentan iprd program primarily consist clinical trial cost length success extremely difficult predict obtain necessary regulatory approval numerous risk uncertainty exist prevent completion development include ability enroll patient clinical trial possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain darusentan treatment resistant hypertension approve united states country outside united states marketing approval significant limitation use future discussion regulatory agency determine datum need timeline review differ materially current projection darusentan successfully commercialize result strategic decision discontinue development darusentan example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result table content purchase iprd expense corus represent estimate fair value coruss incomplete inhale aztreonam lysine cf rd program reach technological feasibility alternative future use acquisition date expense acquisition description program acquisition date update subsequent change status development follow estimate acquisition date fair value program description status development million inhale aztreonam lysine cf aztreonam formulation inhalation gram phase clinical trial acquisition date file nda fda negative bacteria cause lung infection patient cf november grant target review date september estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate fair value purchase iprd present value discount rate base estimate internal rate return coruss operation comparable estimate weighted average cost capital company coruss profile represent rate market participant use value purchase iprd project cash flow aztreonam lysine inhalation program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market coruss early stage candidate include valuation purchase iprd earlystage project identifiable revenue expense associate purpose estimate fair value aztreonam program estimate program approximately complete acquisition date base estimate time cost complete remain effort include completion phase clinical development prepare filing nda fda acquisition date estimate incur future rd cost approximately million million date acquisition include year commercialization expect occur material net cash inflow estimate begin aztreonam program assume necessary regulatory approval received product successfully commercialize date remain effort complete coruss iprd program primarily consist obtain necessary regulatory approval fail obtain fda regulatory body approval risk prevent completion development feedback regulatory authority require modification delay later stage clinical trial additional trial perform certain aztreonam lysine inhalation treatment cf approve united states country outside united states marketing approval significant limitation use aztreonam lysine inhalation successfully commercialize result strategic decision discontinue development aztreonam lysine inhalation example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result table content interest income net record interest income net million million million respectively decrease compare primarily attributable low average cash investment balance writedown million million relate otherthantemporary impairment investment achillion pharmaceutical inc assetbacked commercial paper structure investment vehicle respectively increase compare primarily attributable high average cash investment balance interest expense april issue million principal convertible senior note note million principal convertible senior note note collectively note private placement pursuant rule securities act amend note note issue par bear interest rate respectively debt issuance cost million connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note incur interest expense million million million respectively decrease interest expense compare primarily attributable repayment quarter remain amount term loan enter december increase interest expense compare primarily interest term loan interest note minority interest minority interest consolidate financial statement primarily reflect bmss interest operating result joint venture bms united states joint venture form develop commercialize atripla united states primary beneficiary joint venture determine fasb interpretation r amend consolidation variable interest entity consolidate operation joint venture consolidated financial statement provision income taxis provision income taxis million million million respectively effective tax rate differ federal statutory rate primarily state taxis offset tax credit certain operating earning nonus subsidiary consider indefinitely invest outside united states include operate income pretax charge million billion iprd expense associate corus myogen acquisition respectively record income tax benefit relate purchase iprd expense amount nondeductible effective tax rate differ federal statutory rate primarily federal tax nondeductible purchase iprd expense state taxis offset tax credit certain operating earning nonus subsidiary consider indefinitely invest outside united states effective tax rate differ federal statutory rate generally state taxis offset recognition previously unbenefitte net operating loss tax credit carryforward certain operating earning nonus subsidiary consider indefinitely invest outside united states onetime benefit qualifying dividend american job creation act ajca october ajca sign law ajca allow deduction certain qualified foreign earning repatriate define ajca elect apply provision qualify earning repatriate earning repatriation result onetime tax provision benefit approximately million recognize table content june fasb issue fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return fin provide guidance derecognition classification interest penalty account interim period disclosure transition fin effective fiscal year begin december january adopt fin increase liability unrecognized tax benefit million corresponding charge opening balance accumulate deficit permit fin addition reclassify million unrecognized tax benefit shortterm income taxis payable noncurrent defer tax asset longterm income taxis payable date adoption total federal state foreign unrecognized tax benefit million record primarily longterm income taxis payable consolidated balance sheet include accrue liability relate interest million total unrecognized tax benefit million recognize reduce effective tax rate period recognition permit provision fin continue classify interest penalty relate unrecognized tax benefit income tax provision consolidated statement operation december total federal state foreign unrecognized tax benefit million include interest million total unrecognized tax benefit million recognize reduce effective tax rate period recognition respect unrecognized tax benefit currently unable reasonably reliable estimate period cash settlement respective tax authority liquidity capital resource follow table summarize cash cash equivalent marketable security work capital cash flow activity end year thousand december cash cash equivalent marketable security working capital year end december cash provide operating activity invest activity financing activity cash cash equivalent marketable security cash cash equivalent marketable security total billion december increase billion december increase billion primarily attributable net cash provide operation billion proceed issuance stock employee stock plan million increase partially offset repurchase million common stock stock repurchase program repayment remain amount term loan million capital expenditure million relate expansion facility accommodate growth table content cash cash equivalent marketable security total billion december decrease december decrease million primarily net cash pay billion acquisition myogen raylo corus million pay principal outstanding term loan enter decrease partially offset net cash provide operation billion net proceed million issuance note relate transaction proceed issuance stock employee stock plan million work capital work capital december billion compare billion december significant factor result increase work capital million increase cash cash equivalent shortterm marketable security primarily cash provide operating activity proceed issuance stock employee stock plan partially offset repurchase common stock repayment term loan capital spend million increase prepay taxis relate intercompany profit gilead joint venture million increase account receivable primarily increase sale work capital december billion compare billion december significant factor result decrease work capital billion decrease cash cash equivalent shortterm marketable security primarily fund significant acquisition activity decrease marketable security portfolio decrease result classification certain marketable security longterm security million increase account payable primarily launch atripla july relate purchase efavirenz bms bmss approximate market value efavirenz order joint venture build inventory level supply increase atripla demand work capital decrease partially offset million increase inventory primarily increase atripla inventory include efavirenz purchase bms bmss approximate market value efavirenz million increase account receivable primarily increase sale low collection receivables certain european country collection traditionally slow cash provide operating activity cash provide operating activity billion comprise primarily billion net income adjust noncash item million stockbase compensation expense million defer income taxis million tax benefit relate employee stock plan million excess tax benefit stock option exercise partially offset million net cash outflow relate change operate asset liability table content cash provide operating activity billion comprise primarily billion net loss adjust noncash item billion purchase iprd expense stockbase compensation expense million million tax benefit relate employee stock plan million excess tax benefit stock option exercise partially offset million net cash outflow relate change operate asset liability cash provide operating activity million comprise primarily million net income adjust noncash item million tax benefit employee stock plan partially offset million net cash outflow relate change operate asset liability include million prepay royalty emory relate emtricitabine cash investing activity cash investing activity primarily relate purchase sale maturity availableforsale security capital expenditure acquisition nycome limited cash investing activity primarily relate purchase sale maturity availableforsale security acquisition myogen raylo chemicals inc raylo corus capital expenditure cash investing activity primarily relate purchase sale maturity availableforsale security billion cash investing activity compare billion decrease million decrease primarily acquisition myogen raylo corus total billion cash purchase sale maturity marketable security activity compare billion cash investing activity compare million increase billion increase primarily acquisition myogen raylo corus total billion discuss cash provide purchase sale maturity marketable security activity compare capital expenditure related primarily expansion manufacturing capability upgrade facility spend computer laboratory equipment accommodate business growth capital expenditure include construction new building foster city california headquarters capital expenditure include purchase building previously lease construction cost new building foster city california headquarters december capital expenditure commitment million expect fulfill commitment fund generate operating cash flow cash provide financing activity cash financing activity million primarily result million repurchase common stock stock repurchase program million pay remain amount term loan partially offset proceed issuance stock employee stock plan million million excess tax benefit stock option exercise cash provide financing activity million primarily result million net proceed generate issuance note relate transaction addition receive proceed issuance stock employee stock plan million million excess tax benefit employee stock option exercise cash inflow partially offset million pay principal term loan cash provide financing activity primarily relate proceed million term loan proceed issuance stock employee stock plan million table content information december whollyowne subsidiary gilead biopharmaceutics ireland corporation gbic enter amend restate credit agreement supersede exist revolve credit agreement syndicate bank increase credit facility billion amend restate credit agreement include subfacility swingline loan letter credit term amend restate credit agreement borrow initially aggregate billion revolving credit loan loan amend restate credit agreement bear interest libor plus margin range basis point basis point ii base rate define amend restate credit agreement prepay outstanding borrowing time penalty premium outstanding interest principal payable december connection amend restate credit agreement enter parent guaranty agreement guarantee obligation gbic amend restate credit agreement expect use proceed loan amend restate credit agreement work capital requirement general corporate purpose december million letter credit outstanding amend restate credit agreement august result review term exist corporate aircraft lease consideration alternative available expiration enter agreement purchase aircraft construct delivery aggregate purchase price purchase agreement million december deposit total million record noncurrent asset consolidate balance sheet future deposit term purchase agreement follow million million million million million million option terminate purchase agreement subject maximum payment fullyequippe price aircraft believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire additional manufacturing capability office facility possibility acquire company new product establishment additional collaborative relationship company cost associate defense settlement adverse result litigation government investigation future require additional funding form proceed equity debt financing fund require assure available favorable term offbalance sheet arrangement offbalance sheet arrangement currently material reasonably likely material consolidated financial position result operation table content contractual obligation contractual obligation consist debt obligation capital operating lease purchase obligation primarily form capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact cancelable december thousands payment period contractual obligation total year year year year convertible senior note capital lease obligation operating lease obligation capital commitment purchase obligation clinical trial total december outstanding principal billion note issue april december firm capital project commitment approximately million primarily relate expansion certain aspect manufacturing capability upgrade facility december firm purchase commitment relate active pharmaceutical ingredient certain inventoryrelate activity amount related active pharmaceutical ingredient represent minimum purchase requirement actual purchase expect significantly exceed amount december clinical study clinical trial phase significant clinical trial expenditure cro contract cro cancelable generally cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract addition commit potential future milestone payment party license development program payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table respect total gross unrecognized tax benefit liabilitie million december unable reasonably reliable estimate period cash settlement respective tax authority amount include longterm income taxis payable consolidated balance sheet include table recent accounting pronouncement december fasb issue sfas revise business combination sfas r sfas r establish principle requirement recognize measure asset acquire liability assume noncontrolle interest acquiree business combination sfas r provide guidance recognize measure goodwill acquire business combination require acquirer disclose information need evaluate understand financial effect business combination sfas r effective business combination transaction acquisition date december know sfas r material impact prospective consolidated financial statement table content december fasb issue sfas noncontrolle interest consolidate financial statement amendment accounting research bulletin consolidated financial statement sfas sfas establish accounting reporting standard ownership interest subsidiary hold party parent consolidate net income loss attributable parent noncontrolle interest change parent ownership interest valuation retain noncontrolle equity investment subsidiary deconsolidate sfas establish reporting requirement identify distinguish interest parent interest noncontrolle owner sfas effective fiscal year begin december currently evaluate effect adoption sfas consolidated financial statement item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro british pound australian dollar dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business significant percentage product sale denominate foreign currency enter foreign exchange forward contract foreign exchange option contract partially mitigate impact change currency exchange rate cash flow sale denominate foreign currency hedge portion account receivable balance denominate foreign currency reduce eliminate exposure currency fluctuation date sale record date cash collect general market risk contract offset correspond gain loss transaction hedge recent year foreign currency exchange fluctuation primarily positive impact product sale gross margin impact foreign currency fluctuation moderated hedge program table content follow table summarize notional amount average currency exchange rate fair value open foreign exchange forward option contract december contract maturity month average rate state term dollar foreign currency fair value represent estimate settlement amount december notional amount fair value dollar thousand foreign exchange forward contract notional weight average currency settlement price fair value british pound euro australian dollar total foreign exchange option contract notional weight average currency strike price fair value british pound euro australian dollar total total foreign exchange forward option contract total notional billion total fair value relate liability million open foreign exchange forward option contract december compare total notional billion total fair value relate liability million open foreign exchange forward contract december interest rate risk portfolio availableforsale marketable security fix variablerate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base duration industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return table content follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december dollar thousand year end december total fair value december asset availableforsale debt security average interest rate liability convertible senior note average interest rate capital lease obligation include current portion verage interest rate april issue million principal convertible senior note note million principal convertible senior note note private placement pursuant rule securities act amend note note issue par bear interest rate respectively convert subject certain circumstance credit risk february begin observe fail auction auction rate security underlie asset comprise student loan december hold approximately million auction rate security availableforsale longterm marketable security million security underlie asset comprise student loan auction rate security comprise approximately total cash cash equivalent marketable security december auction rate security include subject fail auction currently rate aaa consistent high quality rating require investment policy believe give cash marketable security position expect operating cash flow access fund credit facility able hold security recovery auction market relate security final maturity account receivable balance december million compare million december growth account receivable balance primarily high product sale hiv product united states europe certain country payment typically slow primarily greece italy portugal spain aggregate account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase credit risk relate certain customer sale customer country tend relatively slowpaye past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total million million day past date experience significant loss respect collection account receivable believe substantially account receivable balance collectible perform credit evaluation customer financial condition generally require collateral table content item financial statement supplementary datum financial statement require item set forth begin report incorporate reference item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness design operation disclosure control procedure define security exchange sec rule control procedure company design ensure information require disclose company report file submit securities exchange act amended exchange act record process summarize report time period specify sec rule form base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define exchange act rule af internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report effectiveness internal control financial reporting december report audit internal control financial reporting appear table content report independent register public accounting firm board director stockholder gilead sciences inc audit gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso criterion gilead sciences incs management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated financial statement gilead sciences inc report date february express unqualified opinion thereon ernst young llp palo alto california february table content c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting stockholder proxy statement heading nominee board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form k amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee certain relationship relate transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service table content iv item exhibit financial statement schedule follow document file annual report index list consolidate financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document agreement plan merger registrant gryphon acquisition sub inc corus pharma inc rodney ferguson phd chairman behalf stockholder representative committee date april stock purchase agreement registrant degussa ag laporte nederland bv raylo chemicals inc date june agreement plan merger registrant mustang merger sub inc myogen inc date october restate certificate incorporation registrant amend certificate amendment restate certificate incorporation registrant certificate designation series junior participate prefer stock registrant amendment certificate designation series junior participate prefer stock registrant amend restate bylaw registrant amend restate reference exhibit exhibit exhibit exhibit exhibit amend restate right agreement registrant chasemellon shareholder services llc date october amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date october second amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date table content exhibit exhibit footnote number description document indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date april indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date april registration right agreement registrant merrill lynch pierce fenner smith incorporate morgan stanley co incorporate banc america securities llc goldman sachs co inc date april form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee form employee proprietary information invention agreement enter registrant certain officer key employee revise september form option agreement stock option plan letter agreement registrant iocbrega date september registrant employee stock purchase plan amend registrant stock option plan relate agreement amend restate april amend january amend january registrants nonemployee directors stock option plan include form option agreement thereunder amend january amend january amendment agreement registrant iocbrega date october amendment agreement registrant iocbrega date december development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september nexstar pharmaceutical incs incentive stock plan adopt february amend settlement agreement registrant successor nexstar pharmaceuticals inc astellas pharma inc successor fujisawa usa inc liposome company inc date august gilead sciences inc defer compensation planbasic plan document gilead sciences inc defer compensation planadoption agreement addendum gilead sciences inc defer compensation plan license agreement gilead sciences limited glaxo group limit date april triangle pharmaceuticals inc stock incentive plan exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date table content exhibit exhibit footnote number description document settlement agreement registrant successor triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited date settlement exclusive license agreement registrant successor triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation date august master clinical commercial supply agreement gilead sciences limited ltd registrant patheon inc date january licensing agreement registrant osi pharmaceuticals inc successor eyetech pharmaceuticals inc date march amend december april amendment licensing agreement eyetech pharmaceuticals inc registrant date amendment licensing agreement osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant date december amendment licensing agreement osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant date august amendment date license agreement date april glaxo group limited gilead sciences limited license agreement japan tobacco inc registrant date march tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date july royalty sale agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july amend restate license agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july form employee stock option agreement equity incentive plan form nonemployee stock option agreement equity incentive plan gilead sciences inc corporate bonus plan amendment supplement date november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc date september restate amend toll manufacturing agreement gilead sciences limited registrant altana pharma oranienburg gmbh date november amend restate agreement registrant successor vestar inc astellas pharma inc successor fujisawa usa inc date june gilead sciences inc code section bonus plan confirmation otc convertible note hedge relate note date april amend restate april registrant bank america na confirmation otc convertible note hedge relate note date april amend restate april registrant bank america na table content exhibit exhibit footnote number description document confirmation otc warrant transaction date april amend restate april registrant bank america na warrants expire confirmation otc warrant transaction date april amend restate april registrant bank america na warrant expire emtricitabine manufacturing supply agreement gilead sciences limited degussa ag date june corus pharma inc stock plan form corus pharma inc stock plan stock option agreement form restrict award agreement equity incentive plan sixth amendment agreement license agreement institute organic chemistry biochemistry academy sciences czech republic k u leuven research development registrant date august amend restate collaboration agreement registrant gilead holding llc bristolmyers squibb company er squibb son llc bristolmyers squibb gilead sciences llc date september form performance share award agreement equity incentive plan license agreement registrant successor myogen inc abbott laboratories date june license agreement registrant successor myogen inc abbott deutschland holding gmbh date october license agreement registrant successor myogen inc glaxo group limit date march addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date form restrict stock unit issuance agreement company credit agreement date december registrant gilead biopharmacentics ireland corporation lender party thereto bank america na administrative agent swing line lender lc issuer parent guaranty agreement date december registrant base salary name executive officer offer letter date october registrant caroline dorsa gilead sciences inc equity incentive plan amend october gilead sciences inc defer compensation plan amend restate effective january gilead sciences inc severance plan amend restate effective january commercialization agreement date december gilead sciences limited bristolmyers squibb company form employee stock option agreement equity incentive plan revise january table content exhibit exhibit footnote number description document form nonemployee director option agreement equity incentive plan initial grant revise january form nonemployee director option agreement equity incentive plan annual grant revise january subsidiary registrant consent independent register public accounting firm power attorney reference signature certification chief executive officer require rule aa rule da securities exchange act amend certification chief financial officer require rule aa rule da securities exchange act amend certification chief executive officer chief financial officer require rule ab rule db section chapter title united states code usc file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form file july incorporate reference file exhibit registrant current report form k file incorporate reference file exhibit registrant current report form k file november incorporate reference file exhibit registrant current report form k file incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form file june incorporate reference file exhibit registrant current report form k file april incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference table content file exhibit nexstar pharmaceutical inc quarterly report form q quarter end june incorporate reference file exhibit nexstar pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceutical inc current report form k file september incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file february incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant registration statement form file august incorporate reference file exhibit myogen inc registration statement form amend originally file august incorporate reference file exhibit myogen inc quarterly report form q file incorporate reference file exhibit registrant current report form k file august incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant current report form k file february incorporate reference management contract compensatory plan arrangement certification accompanie relate deem file security exchange commission incorporate reference file registrant security act amend securities exchange act amend date irrespective general incorporation language contain file certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule b securities exchange act amend table content gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement table content report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth discuss note consolidated financial statement gilead sciences inc change method accounting stockbase compensation accordance guidance provide statement financial accounting standard r sharebase payment audit accordance standard public company accounting oversight board united states gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion thereon ernst young llp palo alto california february table content gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory defer tax asset prepay taxis prepaid expense current asset total current asset property plant equipment net noncurrent portion prepay royalty noncurrent defer tax asset longterm marketable security noncurrent asset total asset liability stockholder equity current liability account payable accrue compensation employee benefit income taxis payable accrue liability defer revenue current portion longterm obligation total current liability longterm defer revenue convertible senior note longterm income taxis payable longterm obligation minority interest commitment contingency stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize share issue outstanding december respectively additional paidin capital accumulate comprehensive income loss retain earning accumulate deficit total stockholder equity total liability stockholder equity accompany note table content gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative purchase inprocess research development total cost expense income loss operation interest income net interest expense minority interest income loss provision income taxis provision income taxis net income loss net income loss sharebasic share share calculationbasic net income loss sharedilute share share calculationdilute accompany note table content gilead sciences inc consolidated statement stockholder equity thousand common stock accumulate retain additional defer earning total paidin comprehensive stock accumulate stockholder share capital income loss compensation deficit equity balance december net income unrealize loss availableforsale security net tax foreign currency translation adjustment unrealize gain cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock compensation compensatory stock transaction balance december net loss unrealize gain availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive loss issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan reversal defer stock compensation compensatory stock transaction assumption stock option connection acquisition purchase convertible note hedge sale warrant defer tax asset convertible note hedge repurchase common stock balance december adoption fin accounting uncertainty income taxis net income unrealize gain availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan compensatory stock transaction repurchase common stock balance december accompany note table content gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash provide operating activity depreciation amortization purchase inprocess research development stockbase compensation expense excess tax benefit stockbase compensation tax benefit employee stock plan defer income taxis noncash transaction change operate asset liability account receivable net inventory prepaid expense asset account payable income taxis payable accrue liability defer revenue minority interest net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security acquisition net cash acquire purchase nonmarketable equity security capital expenditure net cash investing activity financing activity proceed issuance common stock proceed term loan net issuance cost proceeds issuance convertible senior note net issuance cost proceed sale warrant purchase convertible note hedge repurchase common stock repayment longterm debt obligation excess tax benefit stockbase compensation net cash provide financing activity effect exchange rate change cash net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity reclassification achillion equity investment noncurrent asset marketable security achillion initial public offering accompany note table content gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california marketing operation north america europe australia date focus effort bring novel therapeutic treatment lifethreatening disease market expand research development commercial focus include respiratory cardiovascular disease acquisition myogen inc myogen corus pharma inc corus currently market truvada emtricitabine tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection letairis ambrisentan treatment pulmonary arterial hypertension pah vistide cidofovir injection treatment cytomegalovirus cmv infection flolan epoprostenol sodium treatment pulmonary hypertension f hoffmanla roche ltd hoffmanla roche inc roche market tamiflu oseltamivir phosphate treatment influenza royalty pay collaborative agreement manufacture macugen pegaptamib sodium injection manufacturing agreement osi pharmaceuticals inc osi sell macugen treatment neovascular agerelate macular degeneration royalty pay collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary joint ventures bristolmyers squibb company bms primary beneficiary determine financial accounting standard board fasb interpretation revise december consolidation variable interest entity fin r record minority interest consolidate financial statement reflect bmss interest joint venture significant intercompany transaction eliminate consolidated financial statement include result company acquire date acquisition june complete twoforone stock split form stock dividend stockholder record accordingly share share amount period present consolidated financial statement note thereto adjusted retroactively applicable reflect stock split significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis management evaluate estimate include related revenue recognition allowance doubtful account inventory prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate table content gilead sciences inc note consolidated financial statementscontinue revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure recognition revenue product sale provision government rebate customer incentive cash discount prompt payment certain distributor fee estimate future return product expire appropriate item deduct gross product sale government rebate estimate amount payable governmentmanage medicaid program certain qualify federal state foreign government program base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program product sale channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate invoice directly record accrue liability consolidate balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price record allowance account receivable cash discount estimate cash discount base contractual term historical utilization rate expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractuallydetermine covenant maintenance agreedupon inventory level distributor fee base contractuallydetermine fix percentage sale product return provide customer general right product return permit return product damage defective receive customer case product sell unite states product expire accept product return united states expire year expiration estimate expect return expire product base primarily ongoing analysis historical return pattern royalty revenues royalty revenue sale ambisome recognize month follow month correspond sale occur royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur table content gilead sciences inc note consolidated financial statementscontinue contract revenue contract revenue research development rd record performance occur earning process complete base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection reasonably assure revenue nonrefundable upfront license fee milestone payment continue obligation development collaboration obligation supply product recognize performance occur obligation complete accordance specific term gilead obligation type arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet contract revenue include net revenue product distribution service recognize persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure accordance emerge issue task force eitf issue report revenue gross principal versus net agent record product distribution service revenue net supply price pay manufacturerlicensor distribution fee pay specialty pharmacy allowance product return cash discount government rebate contract revenue consolidate statement operation shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement operation research development expense major component rd expense consist personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee overhead allocation consist administrative facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost phase clinical trial pharmaceutical development cost consist expense incur connection product formulation chemical analysis charge rd cost include clinical study cost expense incur consistent statement financial accounting standard sfas accounting research development cost clinical study cost significant component rd expense clinical study perform thirdparty cro accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro monitor level performance significant contract include extent patient enrollment activity communication cro adjust estimate require quarterly basis expense reflect actual effort expend cro material cro contract terminable write notice generally liable actual effort expend cro certain noncancelable expense incur point termination table content gilead sciences inc note consolidated financial statementscontinue amount pay advance relate incomplete service refund contract terminate contract include additional termination payment payable terminate contract additional termination payment record contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million earning loss share basic earning loss share calculate base weightedaverage number share common stock outstanding period dilute earning loss share calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option equivalent assume exercise warrant relate convertible senior note note convertible senior note note collectively note determine treasury stock method note consider instrument c security define eitf issue convertible bond issuer option settle cash conversion eitf conversion spread relate note include diluted earning share calculation potential dilutive share common stock result assume settlement conversion spread note determine method set forth eitf method settlement conversion spread note dilutive effect average share price common stock period exceed note note respectively average share price common stock year end december exceed conversion price note average share price common stock year end december exceed respective conversion price note warrant purchase million million weightedaverage share common stock outstanding year end december respectively include computation dilute earning loss share warrant exercise price great average market price common stock period effect antidilutive stock option purchase approximately million million weightedaverage share common stock outstanding year end december respectively include computation dilute earning loss share option exercise price great average market price common stock period effect antidilutive net loss approximately million weightedaverage number outstanding stock option common stock equivalent include computation dilute net loss share inclusion antidilutive table content gilead sciences inc note consolidated financial statementscontinue follow table reconciliation numerator denominator calculation basic diluted earning loss share thousands year end december numerator net income loss denominator weightedaverage share common stock outstanding calculation basic earning loss share effect dilutive security stock option equivalent conversion spread relate convertible senior note weightedaverage share common stock outstanding calculation dilute earning loss share stockbase compensation prior accordance provision sfas accounting stockbase compensation sfas amend sfas accounting stockbase compensationtransition disclosure elect follow accounting principle board opinion accounting stock issue employee apb fasb interpretation account certain transaction involve stock compensationan interpretation apb opinion accounting employee stockbase plan apb exercise price employee director stock option equal great fair value underlie stock date grant compensation expense recognize consolidated statement operation january adopt provision sfas revise sharebased payment sfas r require sharebase payment employee director include grant stock option recognize consolidated statement operation base fair value sfas r require benefit tax deduction excess recognize compensation cost report consolidated statement cash flow finance cash flow operate cash flow apply modify prospective method adoption method permit sfas r require compensation expense record vest nonveste stock option stockbase award begin quarter adoption sfas r accordance modify prospective method prior period amount restate reflect adoption sfas r addition calculate pool excess tax benefit available additional paidin capital apic accordance provision sfas r cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent enter overnight repurchase agreement repos purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repos major bank authorize dealer provide repos collateralize government security fair value table content gilead sciences inc note consolidated financial statementscontinue fair value security sell eligible instrument investment policy include cash equivalent include commercial paper money market fund bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security include auction rate security variable rate demand obligation time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude earning report separate component stockholder equity interest income net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline result enter collaboration time time hold investment nonpublic company record nonmarketable security cost noncurrent asset amount otherthantemporary impairment regularly review investment indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security policy limit amount invest security duration industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe certain country payment typically slow primarily greece italy portugal spain aggregate account receivable balance significant case slow payment practice country reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total million million day past december past account receivable country total million million day past date experience significant loss respect collection account receivable believe past account receivable net allowance reflect consolidated balance sheet collectible perform credit evaluation customer financial condition generally require collateral table content gilead sciences inc note consolidated financial statementscontinue certain raw material utilize operation obtain single supplier raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship product supply drug candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback government rebate cash discount prompt payment doubtful account sale return estimate wholesaler chargeback government rebate cash discount sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual obligation historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize prepay royalty prepay royalty capitalize cost initially equivalent present value future royalty obligation expect pay licensor expect level product sale incorporate related technology review quarterly expect future sale level product indicator require writedown net recoverable value change estimate life prepay royalty amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast future product sale incorporate related technology review effective royalty rate annually prospectively adjust effective rate base significant new fact circumstance arise review property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method repair maintenance cost expense incur estimate useful life year follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term table content gilead sciences inc note consolidated financial statementscontinue office computer equipment include capitalize software capitalize software purchase internally develop software december unamortize capitalize software cost million consolidated balance sheet amortize million capitalize software cost leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction inprogress include property plant equipment interest million million capitalize respectively significant interest capitalize goodwill intangible asset goodwill represent excess purchase price estimate fair value net asset acquire business combination accordance sfas goodwill intangible asset sfas goodwill amortize require test annually impairment test goodwill impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carry accordance sfas intangible asset definite life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment fda regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate incomeproduce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group estimate future cash flow asset liability group low level identifiable cash flow largely independent cash flow generate group undiscounte future cash flow carry asset asset group impairment loss measure excess carrying value asset asset group estimate fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income loss accumulate separate component stockholder equity net foreign exchange transaction gain loss include interest income net consolidated statement operation net transaction gain total million million million respectively table content gilead sciences inc note consolidated financial statementscontinue hedge certain foreign currency exposure related outstanding trade account receivable forecast product sale foreign exchange forward contract foreign exchange option contract general market risk contract offset correspond gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time limit risk counterpartie contract unable perform transact major bank limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognize unrealized gain outstanding contract ie contract positive fair value date default enter speculative foreign currency transaction hedge net investment foreign subsidiary fair value financial instrument financial instrument consist principally cash cash equivalent marketable security accounts receivable certain noncurrent asset foreign exchange forward option contract account payable longterm debt longterm obligation cash cash equivalent marketable security note foreign exchange contract hedge account receivable note report respective fair value balance sheet foreign exchange contract hedge forecast sale record fair value net relate deferred gain loss result report net balance zero remain financial instrument report consolidated balance sheet amount approximate current fair value income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation exist tax law regulation factor favorable unfavorable effect future effective income tax rate factor include limited interpretation exist tax law change tax law rate account stock option sharebase payment merger acquisition future level rd spending change accounting standard future level capital expenditure changes mix earning tax jurisdiction operate change overall level pretax earning finalization federal state foreign income tax audits impact income tax provision result abovementione factor significant negative impact net income january adopt fasb interpretation accounting uncertainty income taxis fin interpretation sfas accounting income taxis sfas fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return fin provide guidance derecognition classification interest penalty account interim period disclosure transition result adoption fin increase liability unrecognized tax benefit million corresponding charge opening balance accumulate deficit permit fin addition reclassify million unrecognized tax benefit shortterm income taxis payable noncurrent defer tax asset longterm income taxis payable date adoption total federal state foreign unrecognized tax benefit million record primarily longterm income table content gilead sciences inc note consolidated financial statementscontinue taxis payable consolidated balance sheet include accrue liability relate interest million total unrecognized tax benefit million recognize reduce effective tax rate period recognition permit provision fin continue classify interest penalty relate unrecognized tax benefit income tax provision consolidated statement operation recent accounting pronouncement december fasb issue sfas revise business combination sfas r sfas r establish principle requirement recognize measure asset acquire liability assume noncontrolle interest acquiree business combination sfas r provide guidance recognize measure goodwill acquire business combination require acquirer disclose information need evaluate understand financial effect business combination sfas r effective business combination transaction acquisition date december know sfas r material impact prospective consolidated financial statement december fasb issue sfas noncontrolle interest consolidate financial statement amendment accounting research bulletin consolidated financial statement sfas sfas establish accounting reporting standard ownership interest subsidiary hold party parent consolidate net income loss attributable parent noncontrolle interest change parent ownership interest valuation retain noncontrolle equity investment subsidiary deconsolidate sfas establish additional reporting requirement identify distinguish interest parent interest noncontrolle owner sfas effective fiscal year begin december currently evaluate effect adoption sfas consolidated financial statement derivative financial instrument derivative recognize asset liability measure fair value base quote market price enter foreign currency forward option contract hedge change fair value certain monetary asset liability denominate nonfunctional currency record change fair value instrument interest income net derivative instrument designate hedge sfas nos accounting derivative instrument hedge activity collectively refer sfas enter foreign currency forward option contract maturity month hedge percentage future cash flow relate forecasted product sale foreign currency derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify hedge relate forecasted foreign currency product sale designate document inception respective hedge designate cash flow hedge sfas evaluate effectiveness quarterly inception hedge relationship quarterly basis perform regression analysis change cash flow underlie contract regress change cash flow hedge instrument exclude time value assess effectiveness hedge relationship assess hedge effectiveness retrospective basis dollaroffset approach monthly exclude time value effectiveness testing recognize change time value hedge interest income net exclude gain million million million assessment hedge effectiveness respectively effective component hedge record table content gilead sciences inc note consolidated financial statementscontinue accumulated comprehensive income loss unrealize gain loss hedge instrument note hedge forecast transaction occur hedge dedesignate unrealized gain loss reclassify earning time substantially value report accumulate comprehensive income loss december reclassify earning month december net unrealize loss million million respectively open foreign exchange contract gain loss cash flow hedge record product sale increase decrease product sale million million million respectively residual change fair value instrument include result cancellation dedesignation hedge contract ineffectiveness recognize immediately interest income net impact hedge ineffectiveness significant consolidated statement operation notional amount foreign exchange forward option contract outstanding billion december billion december liability fair value million million december respectively acquisition nycome limited september complete acquisition nycome limited nycome whollyowne irish subsidiary germanybase pharmaceutical company nycome gmbh nycome facility locate cork ireland conduct manufacturing tablete operation nycome gmbh transfer certain operation dublin ireland area site facility utilize site primarily solid dose tablet manufacturing exist future product product packaging activity nycome acquisition account business combination accordance sfas business combination sfas result operation nycome completion acquisition september include consolidated statement operation aggregate purchase price nycomed common stock million consist cash pay closing million estimate direct transaction cost million employeerelate severance cost million employeerelate severance cost include purchase price establish workforce reduction plan acquisition transaction accordance eitf issue recognition liability connection purchase business combination eitf purchase price allocate primarily property plant equipment million remain balance allocate net work capital september consider nycome acquisition material business combination sfas disclose pro forma result operation require sfas material business combination connection transfer certain operation dublin ireland area site cork facility finalize personnel plan respect dublin employee meet criterion recognize onetime termination benefit sfas accounting cost associate exit disposal activity fourth quarter estimate termination benefit total approximately million december provide relocation retention benefit total approximately million million respectively employee target relocation cork facility retain provide service certain period time table content gilead sciences inc note consolidated financial statementscontinue myogen inc november complete acquisition outstanding share common stock myogen cash tender offer term agreement plan merger enter october myogen publiclyheld biopharmaceutical company base westminster colorado focus discovery development commercialization small molecule therapeutic treatment cardiovascular disorder myogen product candidate latestage clinical development ambrisentan treatment patient pulmonary arterial hypertension pah darusentan treatment patient resistant hypertension acquisition provide opportunity expand cardiovascular therapeutic area myogen acquisition account business combination accordance sfas result operation myogen november include consolidated statement operation aggregate purchase price myogen common stock billion consist cash pay prior closing billion fair value vest stock option assume million direct transaction cost million consist primarily investment banking fee employeerelate severance cost million reduction income taxis payable million result primarily exercise stock option assume myogen vest acquisition date reduction income taxis payable result decrease aggregate purchase price employeerelate severance cost include purchase price establish workforce reduction plan acquisition transaction accordance eitf accordance merger agreement enter myogen conversion value stock option assume determined base exercise price option purchase share common stock myogen average closing price common stock consecutive trading day immediately precede include tender offer acceptance date november share estimate fair value stock option assume determined average price share approximate price resulted average closing price common stock trading day trading day acceptance date accordance eitf issue determination measurement date market price acquirer security issue purchase business combination fair value stock option assume calculate blackschole valuation model follow assumption expect life range year riskfree interest rate range expect volatility range dividend yield fair value asconverte gilead stock option exceed fair value myogen stock option immediately prior exchange approximately million million asconverte share subject outstanding myogen stock option fully vest acquisition date estimate fair value vest option million include purchase price estimate fair value unvested option million include purchase price recognize stockbase compensation expense remain future vest period option table content gilead sciences inc note consolidated financial statementscontinue follow table summarize purchase price allocation november thousands cash cash equivalent shortterm marketable security account receivable net prepaid expense asset account payable defer revenue liability net tangible asset defer tax asset purchase inprocess research development goodwill total purchase price million defer revenue reflect fair value defer revenue legal performance obligation accordance eitf issue accounting business combination defer revenue acquiree million defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization conclude base standard set forth sfas likely realize benefit defer tax asset elect treat myogen acquisition asset acquisition california state tax purpose purchase inprocess research development iprd goodwill result acquisition deductible california state income tax purpose amount deductible federal income tax purpose estimate fair value purchase iprd billion determined management purchase iprd represent myogen incomplete rd program reach technological feasibility alternative future use acquisition date expense acquisition consolidated statement operation summary program acquisition date update subsequent change status development follow estimate acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic acidclass endothelin phase clinical trial complete prior acquisition date file nda fda receptor antagonist era treatment pah december june fda approve letairis ambrisentan treatment pah united states additionally march european medicine evaluation agency emea validate marketing authorization application ambrisentan treatment pah file collaboration partner glaxosmithkline inc gsk february ambrisentan receive positive opinion european committee human medicinal product treatment pah market volibris gsk approval darusentan orally active etaselective era treatment resistant phase clinical development acquisition date currently phase clinical hypertension development table content gilead sciences inc note consolidated financial statementscontinue estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate fair value purchase iprd present value discount rate base estimate internal rate return myogen operation comparable estimate weighted average cost capital company myogen profile represent rate market participant use value purchase iprd compensate differ phase development ambrisentan darusentan probabilityadjuste estimation expect future cash flow associate program determine time present value expect future cash flow discount rate project cash flow ambrisentan darusentan program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market remain effort complete darusentan iprd program primarily consist clinical trial cost length success extremely difficult predict obtain necessary regulatory approval numerous risk uncertainty exist prevent completion development include ability enroll patient clinical trial possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain darusentan treatment resistant hypertension approve united states country outside united states marketing approval significant limitation use future discussion regulatory agency determine datum need timeline review differ materially current projection darusentan successfully commercialize result strategic decision discontinue development darusentan example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result excess purchase price fair value amount assign asset acquire liability assume million represent goodwill result myogen acquisition record goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas goodwill test impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carry raylo chemicals inc november complete acquisition outstanding share common stock raylo chemicals inc raylo whollyowne subsidiary germanybase specialty chemical company degussa ag locate edmonton canada raylos operations encompass custom manufacture active pharmaceutical ingredient advanced intermediate pharmaceutical biopharmaceutical industry utilize raylo site process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product chemical development activity improve exist commercial manufacturing process table content gilead sciences inc note consolidated financial statementscontinue raylo acquisition account business combination accordance sfas result operation raylo november include consolidated statement operation aggregate purchase price raylo common stock million consist cash pay prior closing million direct transaction cost million employeerelate severance cost million employeerelate severance cost include purchase price establish workforce reduction plan acquisition transaction accordance eitf cost fully pay follow table summarize purchase price allocation november thousands net tangible asset gmp qualification intangible asset goodwill total purchase price million net tangible asset include million cash million property plant equipment million tangible asset assume liability million estimate fair value million associate good manufacturing practice gmp qualification raylos facilities determine management value record intangible asset amortize straightline basis year estimate useful life asset determine management base time derive benefit make substantial upgrade revision acquire manufacturing practice december accumulate amortization asset million million respectively amortization expense recognize million million respectively estimate aggregate amortization expense recognize future year approximately million million excess purchase price fair value amount assign asset acquire liability assume million represent goodwill result raylo acquisition record goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas goodwill test impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carrying elect treat raylo acquisition asset acquisition federal california state tax purpose goodwill result acquisition deductible federal california state income tax purpose prior acquisition raylo longstanding contract manufacturer determine accordance eitf issue accounting preexisting relationship party business combination settlement preexist relationship business combination value need assign preexist relationship purchase price allocation summarize raylos assets acquisition date include million trade receivables eliminate consolidated balance sheet completion acquisition corus pharma inc august complete acquisition corus privatelyheld biopharmaceutical company base seattle washington corus development stage company focus development table content gilead sciences inc note consolidated financial statementscontinue commercialization novel drug respiratory infectious disease corus lead product candidate latestage clinical trial earlystage product candidate acquisition provide opportunity expand respiratory therapeutic area augment pipeline corus acquisition account acquisition asset business combination accordance criterion outline eitf issue determine nonmonetary transaction involve receipt productive asset business sfas corus consider development stage company commence plan principal operation additionally lack necessary element business include complete product ability access customer result operation coru august include consolidated statement operation april purchase million coruss series c prefer stock represent approximately coruss voting equity interest time conjunction purchase series c prefer stock enter agreement plan merger option acquire merger remain outstanding share corus july announce agree exercise option concurrently enter agreement novartis vaccine diagnostics inc novartis novartis agree dismiss litigation corus payment novartis claim novartis directly implicate coruss right develop commercialize product settle novartis deem appropriate allow completion acquisition ensure claim novartis impede ability develop commercialize coruss product candidate settlement result ongoing trial time settlement uncertain sustained period follow close legal appeal potential proceeding completion acquisition include investment coruss series c prefer stock payment novartis acquisition purchase price aggregate purchase price acquire share million consist cash pay prior closing million fair value vest stock option assume million direct transaction cost million employeerelate severance cost million addition holdback million payable corus stockholder year closing merger extent utilize pay claim year assess probable pay holdback record accrue liability consolidate balance sheet acquisition date pay holdback million august employeerelate severance cost include purchase price establish workforce reduction plan acquisition transaction follow table summarize purchase price allocation august thousand net tangible asset assemble workforce net defer tax asset purchase inprocess research development total purchase price million net tangible asset include million cash million investment million tangible asset assume liability million million value assign assemble workforce amortize year estimate useful life asset million net defer tax asset primarily related federal net operating loss tax credit table content gilead sciences inc note consolidated financial statementscontinue carryforward certain state amortization conclude base standard set forth sfas likely realize benefit defer tax asset elect treat corus acquisition asset acquisition california state tax purpose purchase iprd result acquisition deductible california state income tax purpose deductible federal income tax purpose estimate fair value purchase iprd assemble workforce determine management estimate fair value purchase iprd great purchase price pay allocate purchase iprd consist net remain allocate purchase price net tangible asset assemble workforce net defer tax asset purchase iprd represent coruss incomplete rd program reach technological feasibility alternative future use acquisition date expense acquisition consolidated statement operation summary program acquisition date update subsequent change status development follow estimate acquisition date fair value program description status development million inhale aztreonam lysine cystic fibrosis cf aztreonam formulation inhalation gram phase clinical trial acquisition date file nda fda negative bacteria cause lung infection patient cf november grant target review date september estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate fair value purchase iprd present value discount rate base estimate internal rate return coruss operation comparable estimate weighted average cost capital company coruss profile represent rate market participant use value purchase iprd project cash flow aztreonam lysine inhalation program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market coruss early stage candidate include valuation purchase iprd earlystage project identifiable revenue expense associate remain effort complete coruss iprd program primarily consist obtain necessary regulatory approval fail obtain fda regulatory body approval risk prevent completion development feedback regulatory authority require modification delay later stage clinical trial additional trial perform certain aztreonam lysine inhalation treatment cf approve united states country outside united states marketing approval significant limitation use aztreonam lysine inhalation successfully commercialize result strategic decision discontinue development aztreonam lysine inhalation example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give table content gilead sciences inc note consolidated financial statementscontinue underlying assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result acquisition real estate august complete purchase additional building locate foster city california campus aggregate purchase price million purchase price allocate land building land improvement base estimate relative fair value determine management million million million respectively fair value building land improvement depreciate remain useful life asset disposal march receive local city approval proceed demolition building foster city california begin construction new facility include charge associate writeoff building equal aggregate net book value million sga expense availableforsale security follow summary availableforsale security record cash equivalent marketable security consolidate balance sheet estimate fair value availableforsale security base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december debt security treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security debt security total debt security equity security total december debt security treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security debt security total debt security equity security total table content gilead sciences inc note consolidated financial statementscontinue december debt security consist primarily money market fund auction rate security follow table present classification availableforsale security consolidate balance sheet thousand december cash cash equivalent shortterm marketable security longterm marketable security total december portfolio availableforsale debt security comprise million security contractual maturity year billion security contractual maturity great year year million security contractual maturity great year year million security contractual maturity great year security contractual maturity great year comprise assetbacked security include mortgagebacke security auctionrate security follow table present certain information relate sale marketable security thousand year end december gross realize gain sale gross realize loss sale december follow availableforsale debt security continuous unrealized loss position deem otherthantemporarily impair thousand month month great gross gross unrealize estimate unrealized estimate loss fair value loss fair value december treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security total december treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security total table content gilead sciences inc note consolidated financial statementscontinue december gross unrealized loss cause increase yieldtomaturity underlie security approximately total number investment position unrealize loss position significant fact circumstance arise indicate deterioration creditworthiness issuer security base review security include assessment duration severity relate unrealized loss ability intent hold investment maturity otherthantemporary impairment security december result review investment otherthantemporary impairment december record charge million interest income net writedown cost basis investment common stock achillion pharmaceuticals inc achillion assetbacke commercial paper abcp structure investment vehicle million million respectively otherthantemporary impairment achillion base quote market price achillion common stock trading day december compare cost basis assessment base primarily observation quote market value investment carrying value consecutive quarter note otherthantemporary impairment abcp base market factor include estimate fair value underlie collateral abcp december investment common stock achillion abcp million million respectively record longterm marketable security shortterm marketable security respectively consolidated balance sheet european headquarters relocation june announce commercial medical administrative group european headquarters base paris france relocate london area united kingdom european headquarters regulatory safety information technology group locate cambridge area united kingdom believe relocation enable achieve efficiency close proximity group continue position company compete large pharmaceutical company global level french subsidiary continue occupy paris facility continue maintain expand sale marketing presence france quarter relocation plan finalize accrued charge million primarily consist employee severance cost termination benefit include sga expense majority severance cost termination benefit pay reduce relocation accrual include accrue compensation employee benefit consolidate balance sheet insignificant additional cost relate new headquarters united kingdom include recruitment cost legal expense capital expenditure relate cost expense incur significant relocation activity complete aggregate severance relocation recruiting cost result relocation european headquarters total approximately million table content gilead sciences inc note consolidated financial statementscontinue inventory inventory summarize follow thousand december raw material work process finish good total inventory december joint venture form gilead bms include consolidated financial statement hold million million inventory respectively efavirenz active pharmaceutical ingredient purchase bms bmss estimate net selling price efavirenz note establish gilead access program december pursuant truvada viread available substantially reduce price country develop world base regular evaluation forecast sale pricing inventory shelf life conclude fully recover carrying value associate inventory truvada viread gilead access program result record million year end december cost good sell writedown inventory estimate net realizable value consolidate balance sheet detail thousand december property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction inprogress subtotal accumulate depreciation amortization include relate capitalize lease equipment respectively subtotal land total accrue liability accrue government rebate accrue royalty liability total table content gilead sciences inc note consolidated financial statementscontinue collaborative arrangement contract result enter strategic collaboration time time hold investment nonpublic company review interest investee company consolidation andor appropriate disclosure provision fin r december determine certain investee company variable interest entity respect joint venture bms primary beneficiary consolidate investee bristolmyers squibb company north america december enter collaboration bms develop commercialize single tablet regimen contain truvada bmss sustiva united states collaboration structure joint venture operate limited liability company consolidate name bristolmyers squibb gilead sciences llc ownership interest joint venture share product revenue cost reflect respective economic interest bms base proportion net selling price atripla attributable sustiva truvada net selling price truvada change time relative net selling price sustiva bms respective economic interest joint venture vary annually share marketing sale effort bms party obligate provide equivalent sale force effort minimum number year responsible accounting financial reporting tax reporting product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value july joint venture receive approval fda sell atripla united states september bms amend joint venture collaboration agreement allow joint venture sell atripla canada october joint venture receive approval health canada sell atripla canada december joint venture hold sustiva active pharmaceutical ingredient purchase bms bmss estimate net selling price sustiva market include inventory consolidate balance sheet note europe december gilead sciences limited gsl whollyowne subsidiary ireland bms enter collaboration arrangement commercialize distribute atripla european union norway iceland switzerland liechtenstein european territory party form trisupply limited trisupply limited liability company consolidate manufacture atripla distribution europe arrangement trisupply purchase efavirenz bmss estimate net sell price efavirenz european territory responsible product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handling return territory copromote atripla bms responsible accounting financial reporting tax reporting collaboration december european commission approve atripla sale european union december trisupply hold efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidated balance sheet note party form bristolmyers squibb gilead sciences limit limited liability company hold marketing authorization atripla europe primary responsibility regulatory activity table content gilead sciences inc note consolidated financial statementscontinue share marketing sale effort bm major market country party agree provide equivalent sale force effort revenue cost sharing base relative ratio truvada efavirenzs respective net selling price pari gmbh result acquisition corus august assume right february development agreement corus pari gmbh pari development aztreonam lysine inhalation development inhalation delivery device drug product term agreement obligate pay pari service render subject achievement specific milestone obligate pay certain milestone payment pari addition royalty payment base net sale aztreonam lysine inhalation approve commercialization agreement provide right reduce royalty rate payable pari november pay pari million reduce royalty rate agreement aztreonam lysine inhalation approve commercialization record payment rd expense consolidate statement operation lg life sciences ltd november enter license agreement lg life sciences ltd lgls develop commercialize certain caspase inhibitor treatment fibrotic disease agreement grant commercialization right lglss caspase inhibitor include lb know gs term agreement license worldwide exception korea china india lgls retain right lgls retain right develop commercialize caspase inhibitor ophthalmic topical use worldwide accordance term agreement pay million upfront license fee record rd expense consolidate statement operation future alternative use technology agreement obligate fund collaborative research program year identify potential caspase inhibitor drug candidate addition obligate additional milestone payment million achievement certain development regulatory commercial objective obligate pay royalty future net sale product develop approve relation collaboration parion sciences inc august enter research collaboration license agreement parion sciences inc parion research develop commercialize certain epithelial sodium channel inhibitor treatment pulmonary disease agreement grant worldwide commercialization right p gs epithelial sodium channel enac inhibitor discover parion treatment pulmonary disease include cf chronic obstructive pulmonary disease noncf bronchiectasis accordance term agreement pay million upfront license fee record rd expense consolidate statement operation future alternative use technology million investment parion form convertible debt record noncurrent asset consolidate balance sheet collaboration agreement lead development commercialization activity provide funding time equivalent certain research activity addition obligate additional payment achievement certain milestone pay royalty future net sale product develop approve relation collaboration table content gilead sciences inc note consolidated financial statementscontinue roche september enter development license agreement agreement f hoffmannla roche ltd hoffmannla roche inc roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale turn subject reduction certain define manufacturing cost november enter amendment supplement agreement roche amend agreement provide formation joint manufacturing committee review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis case consist representative roche amend agreement option provide specialized sale force supplement roche marketing effort united states tamiflu royalty payable net sale tamiflu sell roche remain amend agreement follow million worldwide net sale give calendar year b million worldwide net sale calendar year c worldwide net sale excess million calendar year amend agreement revise provision agreement relate calculation royalty payment give calendar quarter roche pay royalty base actual royalty rate applicable quarter addition amend agreement royalty payable roche long subject cost good sell adjustment provide agreement roche pay million recognize royalty revenue consist million relate dispute royalty million relate reimbursement cost good adjustment million relate update royalty payable month base thencurrent royalty rate instead prior year effective royalty rate record total million million million tamiflu royalty respectively emory university july royalty pharma purchase royalty interest own emory university emory emtricitabine hiv indication term agreement royalty pharma pay respectively total purchase price million emory exchange elimination emtricitabine royalty emory worldwide net sale product contain emtricitabine result transaction capitalize prepaid royalty share million purchase price million amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast future product sale million million million amortize cost good sell respectively record royalties royalty pharma base actual emtricitabine net sale relative royalty pharma ownership underlie emory royalty interest pay royalty million million million royalty pharma respectively table content gilead sciences inc note consolidated financial statementscontinue july payment million emory connection amendment restatement exist license agreement emory provide great strategic flexibility development emtricitabine hepatitis b indication record payment rd expense expect significant relate rd year prior july pay royalty emory respect emtricitabine hiv indication worldwide license acquire acquisition triangle pharmaceuticals inc triangle pay royalty million net sale emtricitabine institute organic chemistry biochemistry academy sciences czech republic rega stichting enter agreement institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega relate certain nucleotide compound discover institution agreement receive exclusive right manufacture use sell nucleotide compound obligate pay iocbrega percentage net revenue receive sale product contain patented compound subject minimum royalty payment compound cover original agreement include cidofovir active pharmaceutical ingredient vistide adefovir active pharmaceutical ingredient hepsera tenofovir active pharmaceutical ingredient viread active pharmaceutical ingredient truvada atripla december agreement iocbrega amend provide reduce royalty rate future sale product contain tenofovir adefovir return upfront payment million signing agreement payment record prepay royalty classified asset consolidate balance sheet prepay royalty amortize cost good sell expect commercial life tenofovir adefovir amortization million payment begin product launch date viread hepsera december million remain amortized quarterly payment iocbrega base percentage truvada atripla viread hepsera vistide net sale august iocbrega agree waive right royalty sale truvada viread develop country sell product substantially reduce price gilead access program sale atripla distribute merck co inc develop country pay royalty million million million iocbrega respectively japan tobacco inc july grant japan tobacco inc japan tobacco right commercialize viread truvada emtriva japan term agreement receive upfront license fee million receive additional payment achievement certain milestone japan tobacco pay royalty net sale product japan upfront license fee record defer revenue amortize contract revenue period supply product japan tobacco approximately year remain december receive million year milestone payment japan tobacco relate japanese regulatory approval marketing authorization viread emtriva truvada amortize remaining period upfront license fee table content gilead sciences inc note consolidated financial statementscontinue march japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor know gs country world exclude japan japan tobacco retain right term agreement incur upfront license fee million include rd expense future alternative use technology march record million rd expense relate milestone incur result dose patient phase clinical study obligate additional payment achievement milestone pay royalty base future product sale territory market drug achillion pharmaceuticals inc november achillion grant worldwide right research development commercialization certain small molecule hepatitic c virus hcv replication inhibitor involve hcv protease treatment hepatitis c collaboration achillion obligate continue development inhibitor compound accord mutually agree development plan completion proofofconcept clinical study hcvinfecte patient cost incur achieve proofofconcept share equally achillion follow proofofconcept study obligate assume responsibility incur cost associate development commercialization compound warrant development achillion option participate commercialization effort future product arise collaboration conjunction signing collaboration pay million upfront license fee record rd expense future alternative use license technology additionally invest achillion convertible prefer stock agree payment achillion achievement certain milestone outline agreement pay royalty future net sale product arise collaboration october achillion complete initial public offering convertible preferred stock convert share achillion common stock december achillion begin dose hcvinfecte patient phase clinical study gs know ach treatment hepatitis c december record writedown million review otherthantemporary impairment quote market price achillion cost basis consecutive quarter note glaxosmithkline inc april grant gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territory agreement retain right hepsera united states canada europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b territory significant include china japan south korea taiwan receive million milestone payment gsk approval hepsera million milestone payment canadian approval hepsera aggregate million milestone payment commercial approval hepsera japan south korea taiwan receive aggregate million milestone payment gsk achievement gsk consecutive quarter hepsera gross sale exceed million achievement certain drug status china gsk responsibility development commercialization hepsera territory upfront license fee approval milestone record defer revenue total million million million recognize contract revenue respectively table content gilead sciences inc note consolidated financial statementscontinue million balance defer revenue december expect amortize contract revenue remain period supply hepsera gsk agreement approximately year addition gsk require pay royalty net sale gsk generate sale hepsera epivirhbvzeffix gsk hepatitis product gsk territory begin receive royalty gsk sale hepsera quarter record million million million royalty revenue respectively result acquisition myogen november assume right march license distribution supply agreement myogen gsk term license agreement gsk receive exclusive sublicense right ambrisentan certain hypertensive condition territory outside united states receive upfront payment subject achievement specific milestone eligible receive additional milestone payment addition receive step royalty base net sale ambrisentan gsk territory gsk option negotiate exclusive sublicense additional therapeutic use ambrisentan gsk territory term license agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval ambrisentan united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development march receive milestone payment million gsk validation emea marketing authorization application ambrisentan treatment pah milestone upfront license payment million record defer revenue amortize contract revenue remain period performance obligation agreement approximately year february ambrisentan receive positive opinion european committee human medicinal product treatment pah market volibris gsk approval term license agreement distribution supply agreement assume acquisition myogen receive exclusive right market promote distribute flolan sterile diluent flolan united states april osi pharmaceuticals inc march grant osi pharmaceuticals inc osi successor eyetech pharmaceuticals inc worldwide right therapeutic use macugen macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement osi responsible rd cost osi sublicense right macugen territory outside united states pfizer enter license agreement pfizer term contain agreement osi entitle receive payment osi osi reach certain milestone royaltie worldwide net sale macugen subject obligation payment party relate royalty agreement osi expire later year commercial sale product develop date patent expire agreement december enter agreement osi fill finish macugen osi january osi receive fda approval sale macugen united states february macugen approved european union june recognize million milestone payment osi relate commercial sale macugen european union include contract revenue record contract revenue million million million respectively connection clinical supply provide osi milestone achieve osi table content gilead sciences inc note consolidated financial statementscontinue astellas pharma inc enter agreement astellas pharma inc astellas successor fujisawa usa inc relate right market ambisome term agreement amend astella responsible promotion ambisome united states canada exclusive marketing right ambisome rest world subject obligation pay royalty astellas connection sale significant market asia include china india japan south korea taiwan connection sale astella purchase ambisome manufacturing cost sale canada astellas purchase ambisome manufacturing cost plus specify percentage receive royalty equal astellass gross profit sale ambisome united states canada gross profit include deduction cost good sell give current effective royalty rate approximately astellass net sale ambisome united states connection agreement record royalty revenue million million million respectively longterm obligation convertible senior note april issue million principal convertible senior note note million principal convertible senior note note collectively note private placement pursuant rule securities act amend note note issue par bear interest rate respectively debt issuance cost million connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note aggregate principal note sell reflect exercise initial purchaser option purchase additional note cover overallotment note convertible base initial conversion rate share principal note represent initial conversion price approximately share note convertible base initial conversion rate share principal note represent initial conversion price approximately share note convert subject adjustment follow circumstance calendar quarter begin september closing price common stock trading day consecutive trading day period previous quarter applicable conversion price share specified distribution holder common stock specify corporate transaction occur month prior maturity applicable note conversion holder receive cash equal less principal note ii conversion value note conversion value exceed deliver option cash common stock combination cash common stock conversion value excess note convert connection change control require provide makewhole premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal note plus accrue unpaid interest thereon december fair value note note approximately million million respectively base quote market value concurrent issuance note purchase convertible note hedge private transaction cost million cover subject customary antidilution adjustment million share common stock strike price correspond initial conversion price note market value share common stock time conversion note strike price applicable convertible note hedge entitle receive counterpartie transaction cash share common stock combination cash common stock option excess market table content gilead sciences inc note consolidated financial statementscontinue price common stock strike price convertible note hedge convertible note hedge terminate maturity relate note relate note remain outstanding conversion sell warrant acquire million share common stock subject customary antidilution adjustment private transaction receive net proceed million market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price maximum number share common stock issue choose net share settle warrant million share underlie share reserve potential future issuance warrant strike price share warrant expire share warrant expire exercisable respective expiration date take convertible note hedge warrant intend reduce potential dilution future conversion note effectively increase initial conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity choice settle convertible note hedge warrant cash share stock contract meet applicable criterion equity classification outline eitf issue account derivative financial instrument index potentially settle company stock cost convertible note hedge net proceed sale warrant classify stockholder equity addition contract classify stockholder equity index common stock account derivative sfas record defer tax asset million apic effect future tax benefit relate convertible note hedge accordance sfas eitf income tax consequence issue convertible debt beneficial conversion feature contemporaneously close sale note portion net proceed note issuance proceed warrant transaction repurchase million share common stock million stock repurchase program term note agreement require comply certain covenant december compliance covenant credit facility december enter agreement syndicate bank fiveyear million senior credit facility million facility consist uncollateralized million term loan enter gilead biopharmaceutics ireland corporation gbic whollyowne irish subsidiary uncollateralize million revolve credit facility enter parent company gilead sciences inc proceed term loan gbic december facilitate cash dividend distribution million parent company repatriation qualified foreign earning provision american job creation act ajca term term loan minimum principal payment require repay end calendar quarter begin march percent outstanding balance interest accrue rate libor plus tiere contractual rate basis point payable quarterly arrear gbic prepay term loan accrue interest prepay principal time penalty premium parent company whollyowne subsidiary guarantor year end december million term table content gilead sciences inc note consolidated financial statementscontinue loan principal repay year end december repay million represent remain amount term loan time term loan terminate term revolve credit facility enter december interest accrue payable rate libor plus tiere contractual rate basis point payable quarterly arrear parent company prepay outstanding borrowing accrue interest prepay principal time penalty premium outstanding interest principal december payable demand capacity revolve credit facility increase maximum million term loan repay ability irrevocably cancel unutilized portion revolve credit facility proceed obtain revolve credit facility expect work capital capital expenditure general corporate purpose include issuance letter credit million whollyowne subsidiary guarantor december borrowing revolve credit facility january receive waiver noncompliance total debt total capitalization financial covenant year end december contain credit agreement underlie million credit facility acquisitionrelate iprd expenses billion record fourth quarter purchase iprd cause comply financial covenant concurrent waiver prospectively amend credit agreement exclude iprd expense record commencing october definition total consolidated stockholder equity calculation total capitalization total debt total capitalization ratio contain credit agreement december enter amend restate credit agreement supersede exist revolve credit agreement syndicate bank increase credit facility billion amend restate credit agreement include subfacility swingline loan letter credit enter gbic parent company term amend restate credit agreement borrow initially aggregate billion revolving credit loan loan amend restate credit agreement bear interest libor plus margin range basis point basis point ii base rate define amend restate credit agreement prepay outstanding borrowing time penalty premium outstanding interest principal payable december connection amend restate credit agreement parent company enter agreement guarantee obligation gbic amend restate credit agreement expect use proceed loan amend restate credit agreement work capital requirement general corporate purpose december million letter credit outstanding amend restate credit agreement require comply certain covenant amend restate credit agreement december compliance covenant table content gilead sciences inc note consolidated financial statementscontinue capital lease obligation future minimum payment capital lease obligation year end december follow thousand total represent interest total current portion total longterm obligation commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility facility lease san dimas california durham north carolina westminister colorado seattle washington dublin area ireland london area united kingdom expire date lease ireland united kingdom year respectively rent subject increase fifth anniversary respective commencement date facility lease option renew operate lease sale marketing administrative facilities europe canada australia term equipment lease include corporate aircraft vary term renewal option expiration lease term lease expense operating lease total approximately million million million aggregate noncancelable future minimum rental payment operating lease year end december follow thousand legal proceeding united states district court northern district california execute order dismiss entirety prejudice fourth consolidated amend complaint associate purport class action lawsuit chief executive officer chief operating officer chief financial officer executive vice president operation executive vice president research development chief scientific officer senior vice president manufacture senior vice president research allege defendant violate federal security law specifically section b table content gilead sciences inc note consolidated financial statementscontinue security exchange act amend rule b promulgate securities exchange commission make certain allege false misleading statement plaintiff appeal dismissal november receive subpoena united states attorney office san francisco request document market medical education program truvada viread emtriva comply united states attorney subpoena intend cooperate relate government investigation party legal action arise ordinary course business believe legal action material adverse impact business consolidate result operation financial position commitment august result review term exist corporate aircraft lease consideration alternative available expiration enter agreement purchase aircraft construct delivery aggregate purchase price purchase agreement million december deposit total million record noncurrent asset consolidate balance sheet future deposit term purchase agreement follow million million million million million million option terminate purchase agreement subject maximum payment fullyequippe price aircraft normal course business enter firm purchase commitment relate active pharmaceutical ingredient certain inventoryrelate activity december consist follow year million million million million million amount relate active pharmaceutical ingredient represent minimum purchase requirement actual payment purchase relate active pharmaceutical ingredient million million million year end december respectively stockholders equity stock repurchase program march board directors board authorize program repurchase common stock billion twoyear period open market private block transaction pursuant rule b plan privatelynegotiate purchase mean include accelerate stock repurchase transaction similar arrangement april repurchase retire share common stock share aggregate million june repurchase retire aggregate share common stock average purchase price share aggregate purchase price million stock repurchase program expire march intend repurchase common stock program october board authorize new program repurchase common stock billion open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated stock repurchase transaction similar table content gilead sciences inc note consolidated financial statementscontinue arrangement december repurchase retire share common stock share aggregate million billion stock repurchase program remain authorize stock repurchase stock repurchase program terminate december billion use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate apic base estimate average original sale price issue share excess amount charge retain earning accumulate deficit result stock repurchase reduce common stock apic million retain earning million result stock repurchase reduce common stock apic million charge million retain earning prefer stock share authorize preferred stock issuable series board authorize determine designation power preference right series designate share series junior participate prefer stock potential issuance november right agreement mellon investor service llc know chasemellon shareholder services llc amend right plan prefer stock outstanding december december right agreement right plan provide distribution prefer stock purchase right dividend share common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price purchase right purchase right voting privilege attach automatically trade common stock october october board approve amendment right plan amendment provide thing increase exercise price right plan extension term plan november october second amendment provide thing increase exercise price right plan extension term right plan october amendment clarify amendment enter connection increase designate number share series junior participate prefer stock potential issuance right plan stock option plan stockholder approve adopt equity incentive plan amend plan stock option nexstar pharmaceuticals inc nexstar triangle corus myogen stock option plan assume result acquisition nexstar triangle corus myogen convert option purchase common stock effective closing respective acquisition plan broadbase incentive plan allow award grant table content gilead sciences inc note consolidated financial statementscontinue employee director consultant plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option generally vest year exercisable period exceed contractual term year date stock option issue grant price fair value common stock grant date stock option exercise settle newly issue common stock plan previously authorize available pool share stockholder approve increase additional number share common stock available issuance plan december total share common stock authorize grant plan total share common stock reserve issuance share remain available future grant plan follow table summarize activity stock option plan option grant present table exercise price fair value underlie common stock grant date share thousand year end december weight weight weight average average average share exercise price share exercise price share exercise price outstanding beginning year grant assume forfeit exercise outstanding end year exercisable end year weight average grant date fair value option grant year total intrinsic value option exercise year end december million million million respectively total fair value stock option vest year end december million million million respectively december number option outstanding expect vest net estimate future option forfeiture accordance provision sfas r weight average exercise price aggregate intrinsic value million weight average remain contractual life year aggregate intrinsic value stock option outstanding stock option exercisable december billion billion respectively december weight average remain contractual life option outstanding stock option exercisable year respectively table content gilead sciences inc note consolidated financial statementscontinue follow summary stock option outstanding stock option exercisable december option thousand option outstanding option exercisable weighted weighted option average option average range exercise price outstanding exercise price exercisable exercise price total december million unrecognized compensation cost relate stock option expect recognize estimate weighted average period year performance share january grant performancebase share award plan award divide tranche vest performance measurement purpose subject achievement specify market performance goal relative predetermine peer group awards vest threeyear period actual number common stock ultimately issue calculate multiplying number performance share payout percentage range performance share vest committee subcommittee board director determined achieve specified market performance goal fair value marketrelate component performance share estimate grant date monte carlo valuation methodology fair value performancerelate component performance share equivalent grantdate fair value common stock stockbase compensation performance share recognize expense requisite performance period straightline expense attribution approach reduce estimate forfeiture recognize million stockbase compensation expense relate performance share weightedaverage grantdate fair value performance share share december performance share vest million unrecognized compensation cost relate nonveste performance share expect recognize estimate weighted average period year january grant additional performancebase share award term substantially similar award grant single threeyear performance measurement vest period restrict stock award grant restrict stock award nonemployee director plan lieu stock option customarily provide compensation nonemployee directors fair value restrict stock award base fair value common stock date grant restrict stock share vest month date grant grant restrict stock award certain employee plan vest award subject achievement specify performance goal table content gilead sciences inc note consolidated financial statementscontinue follow summary activity relate nonveste restrict stock award year end december weight average grant date fair share value nonveste january grant forfeit vested nonveste december weightedaverage grantdate fair value restrict stock award grant respectively total fair value share vest year end december million million million respectively employee stock purchase plan employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair value common stock offering date purchase date twoyear lookback feature espp cause offer period reset fair value common stock purchase date original offering date espp purchase employee settle newlyissue common stock espps previously authorize available pool share stockholder approve amendment espp increase number share authorize reserved issuance espp additional share common stock extend term espp additional year january share issue espp million total share common stock reserve issuance espp share remain available issuance espp december december million unrecognized compensation cost relate espp expect recognize estimate weightedaverage period year stockbase compensation january adopt provision sfas r require sharebase payment employee director include grant stock option recognize consolidated statement operation base fair value table content gilead sciences inc note consolidated financial statementscontinue table summarize stockbase compensation expense sfas r thousand share amount year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense include net income loss stockbase compensation expense include net income loss share basic diluted year end december capitalize million million stockbase compensation cost inventory respectively stockbase compensation recognize expense requisite service period consolidated statement operation grade vest expense attribution approach nonveste stock option grant prior adoption sfas r straightline expense attribution approach stock option grant adoption sfas r stockbase compensation expense relate stock option recognize adoption sfas r base award ultimately expect vest gross expense reduce estimate forfeiture sfas r require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate estimate forfeiture base historical experience prior adoption sfas r pro forma information require sfas include forfeiture occur result adoption sfas r recognize tax benefit stockbase compensation apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement operation apic table content gilead sciences inc note consolidated financial statementscontinue pro forma information sfas table present net income basic diluted net income share compensation cost stock option plan espp determine base estimate fair value award plan grant purchase date accordance sfa thousand share amount year end december net incomea report add stockbased employee compensation expense include report net income net relate tax effect deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma net income net income share basica report basicpro forma diluteda report dilutedpro forma valuation assumption fair value award grant stock option plan espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life connection adoption sfas r refine methodology derive valuation model assumption calculate estimate fair value award follow assumption year end december expect volatility stock option espp expect life year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant prior adoption sfas r calculate multiple option approach fair value stock option grant begin january calculate single option approach table content gilead sciences inc note consolidated financial statementscontinue prior adoption sfas r historical stock price volatility connection blackschole option valuation model connection adoption sfas r determined blend historical volatility imply volatility trade option common stock well reflection expect volatility expect life stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect life base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout comprehensive income loss comprehensive income loss comprise net income loss certain change stockholder equity exclude net income loss change fair value outstanding effective cash flow hedge change unrealize gain loss availableforsale security change cumulative foreign currency translation account comprehensive income loss year end december include consolidated statement stockholder equity component comprehensive income loss show net relate taxis underlie asset liability hold jurisdiction expect generate future tax benefit liability follow reclassification record connection net realize gain loss sale security cash flow hedge previously include comprehensive income loss thousands year end december net unrealized gain loss relate availableforsale security net tax provision benefit respectively net unrealized gain loss relate cash flow hedge net tax benefit provision respectively reclassification adjustment net tax benefit respectively comprehensive income loss balance accumulate comprehensive income loss net taxis report consolidated balance sheet consist follow component thousand december net unrealized gain availableforsale security net unrealize loss cash flow hedge cumulative foreign currency translation adjustment accumulate comprehensive income loss table content gilead sciences inc note consolidated financial statementscontinue disclosure segment enterprise related information operate business segment primarily focus development commercialization human therapeutic life threaten disease product include segment major product truvada atripla viread emtriva hepsera ambisome account substantially total product sale year end december similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow thousands year end december hiv product truvada atripla viread emtriva total hiv product hepsera ambisome total product sale follow table summarize total revenue external customer collaboration partner geographic region thousand product sale productrelate contract revenue attribute country base shipto location royalty nonproduct relate contract revenue attribute country base location collaboration partner year end december united states outside united states switzerland france spain united kingdom italy germany european country country total revenue outside united states total revenue december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment table content gilead sciences inc note consolidated financial statementscontinue follow table summarize revenue customer individually account total revenue total revenue year end december cardinal health inc mckesson corp amerisourcebergen corp f hoffmannla roche ltd income taxis provision income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer provision income taxis foreign pretax income million million million respectively cumulative unremitted foreign earning consider permanently invest outside united states taxis provide approximately billion million december respectively residual tax liability amount remit approximately million million december respectively difference provision income taxis compute apply federal statutory income tax rate income loss provision income taxis follow thousands year end december income loss provision income taxis tax federal statutory rate state taxis net federal benefit foreign earning different rate purchase inprocess rd expense research credit net unbenefitted stock compensation benefit qualified foreign earning repatriation benefit loss provision income taxis table content gilead sciences inc note consolidated financial statementscontinue deferred income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow thousand december defer tax asset convertible note hedge net operating loss carryforward stockbase compensation capitalize intangible research tax credit carryforward depreciation relate reserve accrual currently deductible net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability unremitte foreign earning total defer tax liability net defer tax asset valuation allowance increase decrease million million million year end december respectively conclude base standard set forth sfas likely realize benefit defer tax asset relate certain state net operating loss tax credit carryforward release million valuation allowance credit goodwill december federal net operating loss carryforward approximately million federal net operating loss carryforward expire date utilize federal tax credit carryforward approximately million expire utilize addition state net operating loss tax credit carryforward approximately million million respectively valuation allowance million provide state net operating loss tax credit carryforward expire date respectively utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization defer tax asset relate tax benefit employee stock option grant reduce reflect exercise exercise result tax deduction excess previously record benefit base option value time grant additional tax benefit credit apic pursuant sfas r table content gilead sciences inc note consolidated financial statementscontinue october ajca sign law ajca allow deduction certain qualified foreign earning repatriate define ajca elect apply provision qualify earning repatriation earning repatriation result onetime tax benefit approximately million include reversal defer tax liability previously accrue unremitted foreign earning million december file federal state foreign income tax return jurisdiction unite states abroad federal california income tax purpose statute limitation remain open year inception utilization net operating loss relate prior year income tax return audit federal state foreign tax authority currently examination internal revenue service tax year franchise tax board california tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction believe position comply applicable law periodically evaluate exposure associate tax filing position record liability relate uncertain tax position accordance fin believe item currently pende material adverse effect consolidated financial statement adverse resolution item period material impact result operation period prior adoption fin record liability relate uncertain tax position base sfas accounting contingency december total federal state foreign unrecognized tax benefit million include interest million total unrecognized tax benefit million recognize reduce effective tax rate period recognition permit provision fin continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement operation respect unrecognized tax benefit currently unable reasonably reliable estimate period cash settlement respective tax authority follow rollforward total gross unrecognized tax benefit liability year end december thousand balance january tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance december table content gilead sciences inc note consolidated financial statementscontinue deferred compensation plan maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead plan gilead plan employee contribute eligible annual compensation subject irs plan limit match contribution gilead plan contribute employee contribution annual maximum match start january contribute employee contribution annual maximum match total matching contribution expense gilead plan million million million maintain deferred compensation plan director key employee defer compensation income tax purpose defer compensation plan nonqualifie defer compensation plan subject qualification requirement section internal revenue code compensation defer december subject requirement section internal revenue code plan officer contribute annual salary annual bonus director contribute annual retainer fee amount defer participant deposit rabbi trust record noncurrent asset consolidate balance sheet begin director elect receive portion annual cash retainer phantom share give participant right receive equal value specify number share specify period time payable share common stock fractional share pay cash establish plan administrator december phantom share outstanding participant elect distribution date available plan receive defer compensation payment quarterly result operation unaudite follow amount thousand share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income net income sharebasic net income sharedilute total revenue gross profit product sale total cost expense net income loss net income loss sharebasic n et income loss sharedilute fourth quarter recognize billion charge purchase iprd associate acquisition quarter recognize million charge purchase iprd associate acquisition table content gilead sciences inc schedule ii valuation qualifying account balance addition balance begin charge end period expense deduction period year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset allowance doubtful account sale return cash discount chargeback valuation allowance defer tax asset include million million december respectively relate acquisition table content